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1.1. The genus Acinetobacter 
 
The Subcommittee on the “Taxonomy of Moraxella and Allied Bacteria” reached an 
agreement on the definition of the genus Acinetobacter in 1971 [1]. The genus 
Acinetobacter was initially classified in the family Neisseriaceae [1]. However, it has 
soon after been re-sorted into the family Moraxellaceae and the following taxonomic 
lineage: Cellular organisms; Bacteria; Proteobacteria; Gamma-proteobacteria; 
Pseudomonadales; Moraxellaceae; Acinetobacter (www.ncbi.nlm.nih.gov/Taxonomy) 
[1, 2]. The genus Acinetobacter can presently be defined as Gram-negative, strictly 
aerobic, non-fermenting, non-fastidious, non-motile, catalase-positive, and oxidase-
negative coccobacillary bacteria with a DNA G and C content of 39% to 47% [1, 2]. 
Nonetheless, Gram staining of Acinetobacter can be variable and the morphologic 
characteristics may change depending on the growth phase [1].  
 
 
1.2. Acinetobacter species 
 
At least 33 species within the Acinetobacter genus have so far been identified, including 
24 named species and 9 currently described as genomic species (gen. sp.) given that no 
phenotypic properties have been found to differentiate them from other species (Table 1) 
[3-21]. Several significant steps in the history of identifying novel Acinetobacter species 
have been achieved [3-21]. In 1986, twelve Acinetobacter genomic species within the 
Acinetobacter genus were identified by DNA-DNA hybridization [3]. Six of these DNA 
groups could be differentiated by phenotypic properties and were given the following 
formal species names: A. calcoaceticus (Acinetobacter gen. sp. 1), Acinetobacter 
baumannii (Acinetobacter gen. sp. 2), Acinetobacter haemolyticus (Acinetobacter gen. 
sp. 4), Acinetobacter junii (Acinetobacter gen. sp. 5), Acinetobacter johnsonii 
(Acinetobacter gen. sp. 7), and Acinetobacter lwoffii (Acinetobacter gen. sp. 8). The 
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study reported an uncertain genotypic and phenotypic differentiation of Acinetobacter 
gen. sp. 9 from A. lwoffii.  
 
In 1988, one novel species was identified by DNA-DNA hybridization [4]. The new 
species was phenotypically distinguished from other Acinetobacter species and was 
named Acinetobacter radioresistens. Five novel genomic species (Acinetobacter gen. sp. 
13BJ, Acinetobacter gen. sp. 14BJ, Acinetobacter gen. sp. 15 BJ, Acinetobacter gen. sp. 
16, and Acinetobacter gen. sp. 17) were subsequently identified by DNA-DNA 
hybridization [5]. Biochemically, the novel DNA groups could not be separated 
unambiguously and therefore were not named. Simultaneously, three novel genomic 
species (Acinetobacter gen. sp. 13TU, Acinetobacter gen. sp. 14TU, and Acinetobacter 
gen. sp. 15TU) were identified by DNA-DNA hybridization [6]. The study also 
reclassified A. radioresistens and Acinetobacter gen. sp. 12 as one species.  
 
In 1991, Acinetobacter gen. sp. 13BJ and Acinetobacter gen. sp. 14TU were found to 
represent one species [7]. The study also showed that strains belonging to A. 
calcoaceticus, A. baumannii, Acinetobacter gen. sp. 3 and Acinetobacter gen. sp. 13TU 
were so similar phenotypically that it was impossible to identify them to the species level 
by the use of biochemical tests. This similarity was in accordance with the observations 
that these four groups were genotypically more closely related to each other than to other 
DNA groups [6]. Accordingly, these four species were suggested to be grouped as the A. 
calcoaceticus-A. baumannii complex [7]. Then in 1993, two novel genomic species 
(Acinetobacter gen. sp. “between 1 and 3” and Acinetobacter gen. sp. “close to 13TU”) 
were identified [8]. The two new species were included within the A. calcoaceticus-A. 
baumannii complex [8]. Successively, one novel species was identified and provisionally 
named as Acinetobacter venetianus [9, 10]. A. venetianus has recently been re-described 
and the name has accordingly been vaidated [11].  
 
In 2001 and 2003, Nemec et al. identified three novel species (Acinetobacter schindleri, 
Acinetobacter ursingii, and Acinetobacter parvus) [12, 13]. Concurrently, seven novel 
species were identified (Acinetobacter baylyi, Acinetobacter bouvetii, Acinetobacter 
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towneri, Acinetobacter tandoii, Acinetobacter grimontii, Acinetobacter tjernbergiae, and 
Acinetobacter gerneri) [14]. However, A. grimontii was later re-classified within the A. 
junii species [15]. One novel species was identified and named as Acinetobacter septicus 
in 2008 although it was soon after re-classified within the A. ursingii species [16, 17].  
 
Three novel species (Acinetobacter soli, Acinetobacter beijerinckii, and Acinetobacter 
gyllenbergii) were also identified in 2008 and 2009 by two different research groups [18, 
19]. Furthermore, Acinetobacter gen. sp. 10, Acinetobacter gen. sp. 11, Acinetobacter 
gen. sp. 3, and Acinetobacter gen. sp. 13TU have recently been named Acinetobacter 
berezinae, Acinetobacter guillouiae, Acinetobacter pittii, and Acinetobacter 
nosocomialis, respectively, given that they can phenotypically be differentiated from 
other species within the genus Acinetobacter [20, 21]. 
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Table 1. Type and reference strains for currently identified Acinetobacter spp. and their corresponding rpoB GenBank accession numbers 





(Acinetobacter gen. sp. 1) 
B46T = CIP 81.8T = ATCC 23055T = DSM 30006T = LMG 
1046T = CCUG 12804T = NCCB 22016T = NIPH 2245T = 
RUH 2201T 
DQ207474 = EF611388 
= EU477149 
[3, 16, 19, 20, 22] 
Acinetobacter baumannii (Acinetobacter 
gen. sp. 2) 
CIP 70.34T = ATCC 19606T = DSM 30007T = LMG 1041T 
= CCUG 19096T = NCCB 85021T = NIPH 501T = RUH 
3023T 
DQ207471 = EF611384 
= EU477108 
[3, 16, 19, 20, 22] 
Acinetobacter pittii (Acinetobacter gen. 
sp. 3) 
CIP 70.29 = ATCC 19004 = LMG 1035 = NIPH 519 = RUH 
2206 
EU477114 [3, 19-21] 
Acinetobacter haemolyticus 
(Acinetobacter gen. sp. 4) 
B40T = CIP 64.3T = ATCC 17906T = DSM 6962T = LMG 
996T = CCUG 888T = NCCB 85026T = NIPH 510T = LUH 
9705T = CCM 2358T 
DQ207484 = EU477109 
= EF611391 
[3, 16, 19, 20, 22] 
Acinetobacter junii (Acinetobacter gen. 
sp. 5 and Acinetobacter grimontii) 
B10T = CIP 64.5T = ATCC 17908T = DSM 6964T = LMG 
998T = CCUG 889T = RUH 2228T = NIPH 551T = CCM 
2376T 
DQ207486 = EU477110 
= EF611394d 
[3, 14-16, 19, 20, 22] 
Acinetobacter gen. sp. 6 CIP A165 = ATCC 17979 = LMG 1026 = CCUG 26492 = 
NIPH 520 = RUH 2867 
DQ207480 = EU477115 [3, 19, 20, 22] 
Acinetobacter johnsonii (Acinetobacter 
gen. sp. 7) 
B8T = CIP 64.6T = ATCC 17909T = DSM 6963T = LMG 
999T = CCUG 19095T = NIPH 518T = RUH 2231T 
DQ207485 = EU477113 [3, 19, 20, 22] 
Acinetobacter lwoffii (Acinetobacter gen. 
sp. 8 and Acinetobacter gen. sp. 9) 
CIP 64.10T = ATCC 15309T = DSM 2403T = LMG 1029T = 
CCUG 12805T = NCCB 83025T = NIPH 512T = CCM 5581T 
= RUH 2219T 
EU477111 = EF611395 
= DQ060363e 
[3, 16, 19, 20] 
Acinetobacter berezinae (Acinetobacter 
gen. sp. 10) 
CIP 70.12T = ATCC 17924T = LMG 1003T = CCUG 26493T 
= NCCB 82031T = NIPH 521T = RUH 2224T 
DQ207475 = EU477116 [3, 19, 20, 22] 
Acinetobacter guillouiae (Acinetobacter 
gen. sp. 11) 
B94T = CIP 63.46T = ATCC 11171T = DSM 590T = LMG 
988T = CCUG 2491T = NCIB 8250T = NIPH 522T 
DQ207476 = EU477117 [3, 19, 20, 22] 
Acinetobacter radioresistens 
(Acinetobacter gen. sp. 12) 
FQ-1T = IAM 13186T = CIP 103788T = ATCC 43998T = 
DSM 6976T = LMG 10613T = CCUG 56440T = NIPH 513T 
= RUH 2865T = CCM 3588T 
DQ207489 = EU477112 
= EF611400 
[3, 4, 6, 16, 19, 20, 
22] 
Acinetobacter gen. sp. 13BJ 
(Acinetobacter gen. sp. 14TU) 
CIP 64.2 = ATCC 17905 = LMG 995 = CCUG 887 = NIPH 
1860 = RUH 2218 = LUH 9704 
DQ207478 = EU477149 [3, 5, 6, 19, 20] 
Acinetobacter gen. sp. 14BJ Bouvet 513 = CCUG 14816 = NIPH 2112 = LUH 1726 EU477147 [5, 19, 20] 
Acinetobacter gen. sp. 15BJ SEIP 23.78 = CCUG 26494 = NIPH 1866 = LUH 1729 EU477133 [5, 19, 20] 
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Table 1. Type and reference strains for currently identified Acinetobacter spp. and their corresponding rpoB GenBank accession numbers (cont.) 




Acinetobacter gen. sp. 16 CIP 70.18 = ATCC 17988 = LMG 1031 = CCUG 996 = 
NIPH 1872 
DQ207477 = EU477135 [5, 19, 20, 22] 
Acinetobacter gen. sp. 17 Bouvet 942 = SEIP Ac87.314 = CCUG 34437 = NIPH 1867 
= LUH 1736 
EU477134 [5, 19, 20] 
Acinetobacter nosocomialis 
(Acinetobacter gen. sp. 13TU) 
CIP 70.11 = ATCC 17903 = DSM 30010 = LMG 993 = 
CCUG 26488 = NIPH 523 = RUH 2210 
EU477118 [6, 19-21] 
Acinetobacter gen. sp. 15TU M 151a = CCUG 26390 = NIPH 546 = LUH 1090 EU477119 [1, 6, 19, 20] 
Acinetobacter gen. sp. ‘between 1 and 3’ Gerner-Smidt 10095 = CCUG 34786 =NIPH 817 = LUH 
1469 
EU477122 [8, 19, 20] 
Acinetobacter gen. sp. ‘close to 13TU’ Gerner-Smidt 10090 = CCUG 34785 =NIPH 973 = LUH 
1472 
EU477126 [8, 19, 20] 
Acinetobacter venetianus RAG-1T = ATCC 31012T = LMG 19082T = CCUG 45561T = 
NIPH 1925T = LUH 3904T 
EU477136 [10, 19, 20] 
Acinetobacter ursingii (Acinetobacter 
septicus) 
CIP 107286T = ATCC BAA-617T = DSM 16037T = LMG 
19575T = NCCB 100021T = CCUG 45559T = NIPH 137T = 
LUH 3792T 
DQ231239 = EF611406 
= EU477105 
[12, 16, 17, 19, 20, 
22] 
Acinetobacter schindleri CIP 107287T = ATCC BAA-618T = DSM 16038T = LMG 
19576T = NCCB 100022T = CCUG 45560T = NIPH 1034T = 
LUH 5832T
DQ207490 = EU477128 
= EF611402 
[12, 16, 19, 20, 22] 
Acinetobacter parvus CIP 108168T =DSM 16617T =  LMG 21765T = CCUG 
48800T = NIPH 384T = LUH 4616T 
DQ207488 = EU477107 
= EF611399 
[13, 16, 19, 20, 22] 
Acinetobacter baylyif NIPH 2312 = ADP1 EU477155 =  CR543861 [19, 20, 23] 
Acinetobacter bouvetii 4B02T = CIP 107468T = DSM 14964T = CCUG 50766T = 
NIPH 2281T = CCM 7196T 
DQ207473 = EU477150 
= EF611387 
[14, 16, 19, 20, 22] 
Acinetobacter towneri AB1110T = CIP 107472T = DSM 14962T = CCUG 50769T = 
NIPH 2286T = CCM 7201T 
DQ207493 = EU477154 
= EF611405 
[14, 16, 19, 20, 22] 
Acinetobacter tandoii 4N13T = CIP 107469T = DSM 14970T = CCUG 56317T = 
NIPH 2284T = CCM 7199T 
DQ207491 = EU477152 
= EF611403 
[14, 16, 19, 20, 22] 
Acinetobacter tjernbergiae 7N16T  = CIP 107465T = DSM 14971T = CCUG 50768T = 
NIPH 2285T = CCM 7200T 
DQ207492 = EU477153 
= EF611404 
[14, 16, 19, 20, 22] 
Acinetobacter gerneri 9A01T = CIP 107464T = DSM 14967T = CCUG 56316T = 
NIPH 2282T = CCM 7197T 
DQ207482 = EU477151 
= EF611389 
[14, 16, 19, 20, 22] 
Acinetobacter soli B1T  = CCUG 59023T = KCTC 22184T = JCM 15062T  Not determined [18] 
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Table 1. Type and reference strains for currently identified Acinetobacter spp. and their corresponding rpoB GenBank accession numbers (cont.) 




Acinetobacter beijerinckii CCUG 51249T = NIPH 838T = LUH 4759T EU477124 [19, 20] 
Acinetobacter gyllenbergii CCUG 51248T = NIPH 2150T = RUH 422T EU477148 [19, 20] 
agen. sp., genomic species; commonly accepted names are presented in bald; other putative names are presented in parenthesis.  
bCIP, Collection de l'Institut Pasteur (France); ATCC, American Type Culture Collection (the United States of America); DSM, Deutsche Sammlung von 
Mikroorganismen (Germany); LMG, Laboratorium voor Microbiologie Gent (Belgium); CCUG, Culture Collection, University of Gothenburg (Sweden); NCCB, 
The Netherlands Culture Collection of Bacteria (The Netherlands); NIPH, National Institute of Public Health (Czech Republic); LUH and RUH, collection of 
Leiden University Medical Center (The Netherlands); CCM, Czech Collection of Microorganisms (Czech Republic); IAM, collection of Institute of Applied 
Microbiology, University of Tokyo (Japan); SEIP, collection of Service des Enterobacteries de l'Institut Pasteur (France); KCTC, Korean Collection for Type 
Cultures (Korea); JCM, Japan Collection of Microorganisms (Japan); T, type strain. 
cNucleotide similarity was compared only for zone 1 (between positions 2916 and 3267) of the rpoB gene.  
dIncorrectly deposited under the name A. johnsonii DSM 6964 (GenBank accession no. EF611394). 
eDifferent from DQ207487 of A. lwoffii CIP 64.10T. 
frpoB of A. baylyi type strain B2T = CIP 107474T = DSM 14961T = LMG 24678T = CCUG 50765T; GenBank accession nos. DQ207472 and EF611386 were 





1.3. Species identification 
 
Identification of Acinetobacter isolates to the species level has been problematic [24]. 
Phenotypic schemes are generally insufficient [1, 7, 24]. Furthermore, phenotypic 
identification by commercial colorimetric systems has been associated with poor 
accuracy [24, 25]. For instance, one study conducted in 2009 reported an incorrect 
speciation of 75% of the isolates using the VITEK 2 GNI identification system [25]. On 
the other hand, molecular identification of Acinetobacter species by DNA-DNA 
hybridisation most likely represents the reference standard method for precise 
identification [1, 3]. However, this method is not appropriate for practical work in routine 
clinical laboratories since it is time-consuming, labour-intensive, and not widely available 
[1].  
 
Other genotypic methods have, therefore, been proposed for fast and yet accurate 
identification of Acinetobacter species either by whole-genome fingerprinting or by 
restriction enzyme or sequence analysis of a particular gene/genetic region (Table 2) [24]. 
Alternatively, protein fingerprinting using a matrix-assisted laser desorption ionization-
time-of-flight (MALDI-TOF) mass spectrometer has been found to represent a promising 
molecular method for rapid identification of Acinetobacter species with high-throughput 
capability [26]. The study showed that the MALDI-TOF Mass Spectrometry system was 
able to separate a total of 552 well-characterized Acinetobacter strains into distinct 
clusters representing 15 different species [26]. 
 
Detection of the blaOXA-51-like gene intrinsic to A. baumannii and detection of an internal 
208-bp fragment from the 16S-23S rDNA intergenic spacer region specific of A. 
baumannii represent two PCR-based molecular methods recommended for rapid sorting 
of A. baumannii isolates [27, 28]. Similarly, detection of the blaOXA-134-like gene intrinsic 
to A. lwoffii could be a putative method for rapid sorting of isolates belonging to this 
particular species [29]. 
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Table 2. Molecular methods for Acinetobacter species identification 
Method Reference 
1. Whole-genome DNA-DNA hybridisation [3] 
2. Whole-genome fingerprinting   
Amplified fragment length polymorphism (AFLP) [30] 
3. Restriction enzyme analysis of a particular gene/genetic region   
16S rDNA (ARDRA)a [31] 
16S-23S rDNA intergenic spacer region [32] 
recA [33] 
4. Sequence analysis of a particular gene/genetic region  
16S rDNA [34] 




5. Analysis of amplicon base composition of several genes (loci)  
Multilocus PCR followed by electrospray ionization mass spectrometry 
(PCR/ESI-MS) 
[38] 
6. Sequence analysis of several genes (loci)  
Multilocus sequence typing (MLST) [39] 
7. Whole-protein fingerprinting  
Matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) 
mass spectrometry 
[26] 
aAmplified ribosomal DNA restriction analysis 
 
 
1.3.1. Partial rpoB sequence analysis  
 
The degree of polymorphism of housekeeping protein-encoding genes, such as the recA, 
gyrB, and rpoB genes, has been found higher than that of the non-protein-encoding 16S 
rDNA gene [22]. Accordingly, sequence analysis of these genes provides a method with a 
better level of resolution for the identification and taxonomic classification of various 
bacterial species. Sequence analysis of four zones of the RNA polymerase β-subunit 
(rpoB) gene and its flanking spacers has been proposed as a useful molecular method for 
identification of Acinetobacter species (Figure 1) [22].  
 
Sequence analysis of the highly discriminative zone 1, spanning 352 bp between 
positions 2901 and 3250 on the rpoB gene, has in particular been found to represent a 
reliable and rapid identification method for Acinetobacter species [22]. The method, 
named partial rpoB gene sequence analysis, has later on been validated on both a 
collection of Acinetobacter reference strains and a collection of Acinetobacter clinical 
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isolates [40]. All the clinical isolates were separated into distinct Acinetobacter species 
with sequence similarities of ≥97.4% with their respective type strains [40]. Recent 
studies on the delineation of novel Acinetobacter species have exploited the sequence 
analysis of a slightly modified rpoB zone 1, spanning 352 bp between positions 2916 and 




Figure 1. Graphical representation of range site variability in rpoB gene and spacer sequences of 
Acinetobacter species in the present study using SVARAP software. The x axis indicates the positions of 
nucleotides, and the y axis indicates the percent variabilities for 50 nucleotides. Primers that amplified 
spacers rplL-rpoB and rpoB-rpoC and hypervariable partial sequences of rpoB bordered by conserved 




1.4. Clinical significance 
 
Although cases of community-acquired infections caused by Acinetobacter spp. have 
been reported, the primary pathogenic role of these bacteria is undoubtedly to cause 
hospital-acquired infections, mainly among patients at intensive care units (ICU) [1]. 
Acinetobacter spp. have been implicated in ventilator-associated pneumonia, catheter-
related blood stream infections, urinary tract infections, cerebrospinal-shunt-related 
meningitis, and wound infections [1]. The risk factors that predispose individuals to get 
infected with Acinetobacter spp. include: (i) patients with major trauma, particularly 
burns, and patients after major surgeries, (ii) previous antimicrobial therapy, (iii) 
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prolonged hospital and ICU stay, and (iv) utilization of mechanical ventilators, drainage 
tubes, and indwelling catheters [24]. Of important note, the human skin and respiratory 
and gastrointestinal tracts represent important and common sites of colonization by 
Acinetobacter spp. [41]. Accordingly, careful clinical judgment is required to 
differentiate between infection and colonization cases [42]. 
 
 
1.5. Skin, mucus membranes, and gastrointestinal tract colonization 
 
Acinetobacter species are apparently the only group of Gram-negative bacteria that may 
be natural residents of human skin [43]. The human skin can thus be a natural reservoir 
and a probable source of infections of various Acinetobacter species [43, 44]. A study 
from Germany reported high carriage rates of Acinetobacter spp. on human skin and 
mucus membranes among inpatients (~75%) and control non-hospitalized persons 
(~43%) (Table 3) [43]. The most frequently isolated species in that study were A. lwoffii 
(47%) and A. johnsonii (21%). Unpredictably, the clinically important A. baumannii and 
A. nosocomialis species (0.5% and 1%, respectively) were not found to be common 
human skin colonizers [43].  
 
 
Another study from Europe similarly reported high carriage rates of Acinetobacter spp. 
on human skin of healthy humans (~44%) along with the predominance of A. lwoffii 
(Table 3) [44]. On the other hand, a study conducted in Hong Kong showed that the skin 
and mucus membranes carriage rates of A. pittii (32%), A. nosocomialis (14%), and A. 
baumanni (4%) in different groups of patients and healthy subjects were noticeably 
higher than those reported from Europe (Table 3) [45]. Interestingly, A. baumannii 
isolates recovered from the hands of individuals in the community were distinct from 
those recovered from patients in two hospitals in New York, the United States of America 
(USA), indicating that hospitals rather than the community represent a reservoir for 




A study conducted in 2005 investigated the carriage rate of Acinetobacter spp. in faecal 
specimens from non-hospitalized individuals from The Netherlands (Table 3) [47]. The 
study reported a carriage rate of ~25% (31/126 specimens). The predominant species was 
A. johnsonii (17.5%), followed by A. guillouiae (4%) whereas only one sample (0.8%) 
yielded an A. baumannii isolate. Accordingly, the human intestine was found not to 
constitute an important community reservoir of the clinically important A. baumannii 
species [47]. The colonization rate of multidrug resistant A. baumannii in faecal samples 
from hospitalized patients in an intensive care unit in Spain was 41% compared with only 
≤ 1% in faecal samples from non-hospitalized individuals from the United Kingdom 
(UK) and The Netherlands [47, 48]. The Spanish study suggested that the multidrug 
resistant A. baumannii fecal colonization was mainly acquired during ICU 
hospitalizations [48]. Interestingly, a recent study showed that 6 of 7 patients with A. 
baumannii bloodstream infections were colonized in the gastrointestinal tract with 
genetically similar strains preceding their bacteremia [49]. 
18 
 
  Table 3. Distribution of Acinetobacter species on the human skin, mucus membranes, and gastrointestinal tract 
Description of the 
Acinetobacter spp. collection 




138 Acinetobacter skin and 
mucous membrane culture 
isolates obtained between 1993 
and 1994 from 30 patients (107 
isolates) and 17 healthy controls 
(31 isolates) in Germany. 
A. lwoffii (n=61) 
A. johnsonii (n=27) 
A. radioresistens (n=19) 
A. pittii (n=12) 
A. junii (n=8) 
A. nosocomialis (n=2)  
A. baumannii (n=1) 
A. berezinae (n=1) 
Acinetobacter gen. sp. 15TU (n=1) 
Unclassified (n=6) 
ARDRA The Acinetobacter skin and mucous 
membrane carriage rates were 75% (30/40) 
among inpatients and 43% (17/40) among 
control non-hospitalized persons. 
 
Twenty patients and 6 controls were 
colonized with two or more different 
Acinetobacter species at different body 
sites.  
 
One patient was colonized by 5 different 
Acinetobacter species at different body 
sites. In addition, 12 patients and 2 
controls were colonized with two or more 
different Acinetobacter species at a same 
given body site.  
[43] 
112 Acinetobacter skin culture 
isolates obtained from 85 healthy 
volunteers from the United 
Kingdom. 
A. lwoffii (n=68)  
Acinetobacter gen.sp. 15BJ (n=14)  
A. radioresistens (n=9) 
A. pittii (n=4) 
A. haemolyticus/A. johnsonii (n=2) 
A. junii/Acinetobacter gen. sp. 17 
(n=1) 
A. baumannii (n=1) 
Unclassified (n=4) 
ARDRA The Acinetobacter skin carriage rate was 
~44% (85/192) in healthy humans.  
 
17 volunteers were colonised with two 
different Acinetobacter species (n=8) or 
with two different strains of one 
Acinetobacter species (n=9).  
 
Only 2 volunteers were colonised with the 
same Acinetobacter strain indicating a 
very low rate of cross-transmission 





Table 3. Distribution of Acinetobacter species on the human skin, mucus membranes, and gastrointestinal tract (cont.) 
Description of the Acinetobacter 
spp. collection 




349 Acinetobacter skin and mucous 
membrane culture isolates obtained 
between January 1997 and March 
1998 from 49 patients, 62 nurses, 
and 90 new nurses and medical 
students from Hong Kong.  
A. pittii (n=100) 
A. nosocomialis (n=60) 
A. baumannii (n=39) 
Acinetobacter gen. sp. 17 (n=23) 
A. johnsonii (n=10) 
A . radioresistens (n=10) 
A. lwoffii (n=7)  
Acinetobacter gen. sp. 15TU (n=8)  
Acinetobacter gen. sp. 15BJ (n=8)  
A. calcoaceticus (n=6) 
A. berezinae (n=3) 
Acinetobacter gen. sp. 16 (n=2) 
A. junii (n=1) 
A. guillouiae (n=2) 
Acinetobacter gen. sp. 13BJ (n=1) 




The Acinetobacter skin and mucous 
membrane carriage rates were 62% (49/79) 
among inpatients, 30% (62/210) among 
nurses (healthy hospital subjects), and 47% 
(90/192) among new nurses and medical 
students (healthy subjects from the 
community). 
 
50% of the subjects who were positive at 
more than one site had different 
Acinetobacter species. 
 
68% of the subjects who were positive at 
more than one site with the same 
Acinetobacter species showed that the 
isolates belonged to different strains. 
[45] 
35 Acinetobacter isolates obtained 
from faecal samples of non-
hospitalized humans from The 
Netherlands. 
A. johnsonii (n=22) 
A. guillouiae (n=5) 
A. junii (n=2) 
A. ursingii (n=2)  
A. baumannii (n=1) 
A. pittii (n=1) 
A. lwoffii (n=1)  
A. berezinae (n=1) 
ARDRA 
 
The Acinetobacter carriage rate in faecal 
samples of non-hospitalized humans was 
~24.6% (31/126). 
[47] 




1.6. Species distribution in clinical isolates 
 
In one of the first studies on the distribution of Acinetobacter species among human 
clinical isolates, A. pittii was predominant among Acinetobacter clinical isolates from 
Sweden [6]. Later on, species identification of 23 clinical isolates of the A. calcoaceticus-
A. baumannii complex from Denmark showed somewhat equivalent distribution between 
A. pittii (8 isolates), A. nosocomialis (6 isolates), and A. baumannii (5 isolates) [8]. A 
study from Germany reported A. baumannii as the clinically predominant Acinetobacter 
species [50]. However, it is important to mention that identification of the strains at the 
species level in that study was done phenotypically.  
 
Similarly, the majority of Acinetobacter isolates from patients in Belgium and The 
Netherlands were also found to belong to the A. baumannii species [42, 51]. Later on, 
many studies on the distribution of Acinetobacter species in clinical isolates have 
demonstrated the predominance of A. baumannii (Table 4) [40, 52-57]. However, studies 
from The Netherlands, Hong Kong, and Ireland have reported A. pittii as the most 
commonly detected species while studies from Korea and UK have shown high rates of 
occurrence of A. nosocomialis and A. lwoffii, respectively (Table 4) [25, 45, 58-60]. On 
the other hand, nosocomial infections caused by other Acinetobacter species, such as A. 
johnsonii, A. junii, A. parvus, A. radioresistens, A. schindleri and A. ursingii etc, have 
generally been less common and mainly represented as individual case reports. Clinial 
isolates from species other than the A. calcoaceticus-A. baumannii complex were mostly 
obtained in blood cultures and involved in catheter-related bloodstream infections and/or 
endocarditis [59, 61].  A review of the majority of the studies investigating the species 
distribution of Acinetobacter spp. in clinical isolates is presented in Table 4. 
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85 Acinetobacter isolates obtained 
from different sources. 
A. baumannii (n=21) 
A. johnsonii (n=12) 
A. haemolyticus (n=10) 
A. lwoffii (n =9)  
A. pittii (n=4) 
A. junii (n=4) 
A. berezinae (n=4) 
A. calcoaceticus (n=3) 
A. guillouiae (n=3) 
Acinetobacter gen. sp. 6 (n=2) 




A. calcoaceticus isolates were all 
obtained from soil samples. It was not 
possible to undoubtedly separate A. 
lwoffii and Acinetobacter gen. sp. 9 into 
two species. Three of the unclassified 
isolates were described as “close to 
genospecies 1 to 3”. 
 
[3] 
181 Acinetobacter isolates obtained 
from different sources. 
A. baumannii (n=100) 
A. lwoffii (n =25)  
A. haemolyticus (n=13) 
A. junii (n=13) 
A. pittii (n=11) 
A. johnsonii (n=11) 
A. calcoaceticus (n=5) 
Acinetobacter gen. sp. 6 (n=1) 
A. guillouiae (n=1) 
A. radioresistens (n =1) 
Phenotypic scheme A. calcoaceticus isolates were all 
obtained from soil samples. A. 
calcoaceticus, A. baumannii, and A. pittii 
were phenotypically close to each other 
and far separated from all other species. 
A. baumannii and A. pittii were 
differentiated from each other only by 
growth at 44°C. Phenotypic tests were 
not able to differentiate Acinetobacter 
gen. sp. 9 from A. lwoffii. 
[3] 
27 proteolytic Acinetobacter clinical 
isolates differing phenotypically 
from the 12 previously described 
Acinetobacter species. 
Acinetobacter gen. sp. 13BJ (n=9) 
Acinetobacter gen. sp. 16 (n=4) 
Acinetobacter gen. sp. 14BJ (n=3) 
Acinetobacter gen. sp. 15BJ (n =2) 




The five novel species (Acinetobacter 
gen. sp. 13BJ, Acinetobacter gen. sp. 
14BJ, Acinetobacter gen. sp. 15BJ, 
Acinetobacter gen. sp. 16, and 
Acinetobacter gen. sp. 17)    could not be 
separated unambiguously by biochemical 





Table 4. Distribution of Acinetobacter species in human clinical isolatesa (cont.) 




23 clinical isolates phenotypically 
identified to the A. calcoaceticus-A. 
baumannii complex obtained from 
Denmark. 
A. pittii (n=8) 
A. nosocomialis (n=6)  
A. baumannii (n=5) 
Acinetobacter gen. sp. "close to 13TU" 
(n=2) 





420 Acinetobacter clinical isolates 
obtained from 12 hospitals in 
Germany.   
A. baumannii (n=275) 
A. pittii (n=50) 
A. johnsonii (n=26) 
A. lwoffii (n=21) 
A. junii (n=11) 
A. haemolyticus (n=8) 
A. berezinae (n=7) 
A. guillouiae (n=4) 
A. radioresistens (n=2) 
Acinetobacter gen. sp. 6 (n=1) 
Unclassified (n=15) 
Phenotypic scheme 
of Bouvet and 
Grimont 
Acinetobacter spp. were the second most 
common Gram-negative bacteria isolated 
from blood cultures accounting for 
8.12% of all positive blood cultures, after 
E. coli (8.53%) and outnumbering 
Pseudomonas spp. (7.59%).  
[50] 
237 Acinetobacter clinical isolates 
obtained during 1990-1991 from 
different sources from patients 
hospitalized at one hospital in 
Belgium.  
A. baumannii (n=128) 
A. lwoffii (n=18) 
A. haemolyticus (n=14) 
A. pittii (n=7) 
A. johnsonii (n=6) 
A. calcoaceticus (n=3) 
Acinetobacter gen. sp. 6 (n=2) 
A. junii (n=1) 
Unclassified (n=58) 
Phenotypic scheme 
adapted from the 
scheme described 
by Bouvet and 
Grimont 
Acinetobacter spp. accounted for ≤1% of 
positive cultures obtained from skin, 
respiratory tracts, and urinary tracts.  
[51] 
58 Acinetobacter clinical isolates 
collected during 1984 and 1985 from 
43 patients in four intensive care 
units and six patients in other wards 
of a tertiary care hospital in The 
Netherlands. 
A. baumannii (n=49) 
A. pittii (n=8) 
A. calcoaceticus (n=1) 
 
SDS-PAGE - [42] 
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52 blood culture isolates of 
Acinetobacter species other than A. 
baumannii obtained between July 
1990 and December 1991 at one 
institute in Germany.  
A. johnsonii (n=14) 
A. pittii (n=12) 
A. lwoffii (n=10) 
A. junii (n=4) 
A. berezinae (n=4) 
A. radioresistens (n=4) 
A. haemolyticus (n=3) 
Acinetobacter gen. sp. 6 (n=1) 
Unclassified (n=3) 
Phenotypic scheme 
adapted from the 
scheme described 
by Bouvet and 
Grimont 
Acinetobacter spp. accounted for 8.1% of 
the positive blood cultures. A. baumannii 
accounted for 57% of these cultures 
while Acinetobacter species other than A. 
baumannii accounted for 43% of them. 
[52] 
38 Acinetobacter isolates including: 
29 clinical isolates obtained during 
1989/1990 from 21 patients, 6 
environmental isolates also obtained 
during 1989/1990, and 3 clinical 
isolates obtained in 1998 from 3 
patients. All the isolates were 
obtained from a Neonatal Intensive 
Care Unit at one university hospital 
in The Netherlands. 
A. pittii (n=29) 
A. baumannii (n=3) 
Acinetobacter gen.sp. 13BJ (n=3) 
A. junii (n=1) 
Unclassified  (n=2) 
DNA-DNA 
hybridization 
The isolation rate of Acinetobacter was 
8/126 (6.7%) among the environmental 
samples.  
[58] 
91 Acinetobacter blood culture 
isolates obtained between January 
1997 and March 1998 from 79 
patients at one hospital in Hong 
Kong. 
A. pittii (n=37) 
A. baumannii (n=18) 
A. nosocomialis (n =14) 
Acinetobacter gen. sp. 17 (n=3) 
A. berezinae (n=2) 





129 Acinetobacter blood culture 
isolates obtained between 1995 and 
1998 at 24 hospitals from the United 
States of America. 
A. baumannii (n=111)  
A. pittii (n=11) 
A. radioresistens (n=4) 
A. junii (n=2) 
A. guillouiae (n=1) 
Phenotypic scheme 
adapted from the 
scheme described 
by Bouvet and 
Grimont 
Acinetobacter spp. accounted for 1.5% of 
all nosocomial bloodstream infections. 
Intra-hospital clonal spread of a single 
strain occurred in 5 hospitals. 
[53] 
244 Acinetobacter clinical isolates 
obtained in November 2000 from 28 
hospitals in Spain. 
A. baumannii (n=226)  




7/15 of A. pittii isolates grew at 44°C. 
Identification of these isolates was 




Table 4. Distribution of Acinetobacter species in human clinical isolatesa (cont.) 
75 Acinetobacter clinical isolates 
obtained between 2003 and 2005 
from 75 patients at one medical 
center in the United States of 
America. 
A. baumannii (n=73) 
A. pittii (n=1) 
A. johnsonii (n=1) 
PCR/ESI-MS The A. pittii and A. johnsonii two isolates 
contained blaOXA-51-like genes which could 
imply uncertain species identification.  
[55] 
232 non-duplicate consecutive 
Acinetobacter isolates obtained 
between November 2004 and 
November 2005 from different 
sources (sputum, urine, wound, 
blood, and throat) at two hospitals in 
Korea. 
A. baumannii (n=142) 
A. nosocomialis (n=60) 
A. pittii (n=14) 
A. berezinae (n=4) 
A. junii (n=2) 
A. johnsonii (n=1) 
Acinetobacter gen. sp. 14BJ (n=1) 
Unclassified (n=8) 
ARDRA Resistance rates to most antimicrobial 
agents were higher in A. baumannii than 
other Acinetobacter species, except for 
the resistance rate for imipenem which 
was higher in A. nosocomialis than other 
Acinetobacter species, including A. 
baumannii. 
[56] 
50 Acinetobacter clinical isolates 
obtained between 2004 and 2005 at a 
university hospital in Korea and 
identified by the VITEK GNI card as 
belonging to the ACB complex. 
A. baumannii (n=40) 
A. nosocomialis (n=9) 
Acinetobacter gen. sp. "close to 13TU" 
(n=5) 
A. pittii (n=4)
ARDRA - [57] 
99 Acinetobacter clinical isolates 
obtained between February 2001 and 
March 2005 from different sources 
(blood, bone, soft tissue, CSF etc.) 
from four public hospitals in 
Marseille, France. 
A. baumannii (n=52) 
A. pittii (n=27) 
A. haemolyticus (n=10) 
A. schindleri (n=5) 
A. lwoffii 9  (n=4)  
A. nosocomialis (n=1) 
Partial sequence 
analysis of rpoB 
Isolates of Acinetobacter gen. sp. 
‘between 1 and 3’ closely clustered with 
those of A. calcoaceticus. 
 
Isolates of Acinetobacter gen. sp. ‘close 
to 13TU’ closely clustered with those of 
Acinetobacter gen. sp. 13TU.  
[40] 
107 clinical isolates of A. 
calcoaceticus-A. baumannii complex 
obtained in 2005-06 from a Public 
Teaching Hospital in Houston, 
Texas, the United States of America. 
A. baumannii (n=87)  
A. pittii (n=15) 
A. nosocomialis (n=3) 
Unclassified (n=2) 
ARDRA 66 of the A. baumannii isolates belonged 
to two major PFGE clonal types. ≥ 90% 
of the A. baumannii isolates were 
multidrug resistant, compared to 15% of 
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63 non-duplicate Acinetobacter 
clinical isolates collected from April 
through November 2007 at ICUs in 
Korea. 
A. baumannii (n=44)  
A. pittii (n=9) 
A. nosocomialis (n=6) 
A. junnii (n=1) 
A. berezinae (n=1) 
A. baumannii-like species (n=2) 
Partial sequence 




Nineteen A. baumannii isolates belonged 
to ST22 and a single PFGE clone. 
[63] 
114 Acinetobacter clinical isolates 
obtained between May 2005 and 
October 2007 at one hospital in 
Dublin, Ireland. 
A. pittii (n=45) 
A. baumannii (n=25) 
A. johnsonii (n=12) 
A. ursingii (n=8)  
A. lwoffii  (n=7)  
A. calcoaceticus (n=5) 
A. guillouiae (n=4) 
A. nosocomialis (n=2) 
A. radioresistens (n=2) 
A. berezinae (n=1) 
A. haemolyticus (n=1) 
A. schindleri (n=1) 
A. tjernbergiae (n=1)
Partial sequence 
analysis of rpoB 
The study demonstrated the poor 
accuracy of the speciation of 
Acinetobacter species by the VITEK-2 
GNI identification system, with 75% of 
isolates erroneously speciated.  
 
[25] 
96 Acinetobacter clinical isolates 
obtained from 10 university hospitals 
in Korea between November 2006 
and August 2007. The isolates 
caused either bacteremia (n=60) or 
urinary tract infections (n=36). 
A. baumannii (n = 59) 
A. nosocomialis (n=19) 
A. pittii (n=7) 
A. junii (n=5) 
A. calcoaceticus (n=2) 
Acinetobacter gen. sp. 16 (n=2) 
A. berenziae (n=1) 
A. baylyi (n=1) 
Partial sequence 
analysis of rpoB 
and gyrB-based 
multiplex PCR 
A. nosocomialis and A. pittii were more 
frequently isolated from patients with 
UTIs whereas A. junii was isolated 
exclusively from patients with 
bacteremia. Thirty-three A. baumannii 
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359 Acinetobacter clinical isolates 
from 331 patients collected between 
1999 and 2006 at the Leiden 
University Medical Centre, The 
Netherlands. 
A. baumannii (n=129) 
A. pittii (n=93) 
A. lwoffii (n =38)  
A. ursingii (n=15)  
A. johnsonii (n=13) 
A. junii (n=12) 
A. nosocomialis (n=9) 
A. calcoaceticus (n=6) 
A. beijerinckii (n=5)  
A. berezinae (n=4) 
A. guillouiae (n=4) 
A. radioresistens (n =4) 
Acinetobacter gen. sp. 15TU (n=3) 
A. haemolyticus (n=3) 
Acinetobacter gen. sp. 14BJ (n=3) 
A. gyllenbergii (n=2) 
Acinetobacter gen. sp. "close to 13TU" 
(n=1) 
Acinetobacter gen. sp. "between 1 and 3" 
(n=1) 
A. parvus (n=1) 
Acinetobacter gen. sp. 16 (n=1) 
Unclassified (n=12) 
AFLP Profile similarity cut-off levels of 50%, 
80%, and 90% were used for species, 
clone, and strain/cluster identification, 
respectively. A. baumannii and A. pittii 
were most frequently isolated from 
sputum and wound samples whereas A. 
lwoffii was mainly isolated from blood 
samples or intravascular lines. A large 
cluster of A. baumannii (involving 31 
patients) and 16 small clusters of various 
species (involving in total 39 patients) 
were observed. 
[64] 
547 Acinetobacter clinical isolates 
obtained in 2008 from 19 different 
hospitals in six provinces of Korea. 
A. baumannii (n= 388) 
A. nosocomialis (n=82) 
A. pittii (n=62) 
A. berenziae (n=13) 
Acinetobacter gen. sp. 13BJ (n=2) 
ATB 32 GN system 
and sequence 
analysis of 16S–23S 
rDNA intergenic 
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690 Acinetobacter clinical isolates 
obtained during 2008/2009 from 135 
hospitals in the United Kingdom. 
A. baumannii (n = 538) 
A. lwoffii (n =61)  
A. ursingii (n =28)  
A. pittii (n=12) 
A. johnsonii (n=11) 
A. parvus (n=9) 
Acinetobacter gen. sp. 13BJ (n=6) 
A. radioresistens (n =4) 
A. baylyi/A guillouiae (n=3) 
A. calcoaceticus (n=3) 
A. nosocomialis (n=2) 
A. haemolyticus (n=2) 
A. junii (n=2) 
A. beijerinckii (n=1)  
A. berenziae (n=1) 
A. gyllenbergii (n=1) 
A. schindleri (n=1) 
Acinetobacter gen. sp. 15TU (n=1) 
Acinetobacter gen. sp. 16 (n=1) 
Unclassified (n=3) 
Partial sequence 
analysis of rpoB 
A. baylyi and A guillouiae clustered too 
closely to be distinguished from one 
another. Three isolates did not cluster 
closely enough with any of the described 
species. For all three, the closest 
currently described species was A. 
towneri.  
[59] 
aSome studies included both clinical and environmental samples. 
bARDRA, amplified 16S rDNA restriction analysis; SDS-PAGE, cell envelope protein sodium dodecyl sulphate-polyacrylamide gel electrophoresis; PCR/ESI-
MS, polymerase chain reaction/electrospray ionization mass spectrometry; AFLP, Amplified fragment length polymorphism.  
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1.7. Antibiotic resistance 
 
Treatment of Acinetobacter infections has conventionally involved the use of ß-lactams, 
aminoglycosides, and quinolones [1]. However, the increased use of these antibiotics has 
resulted in a widespread emergence of antibiotic resistant strains [1]. Carbapenems, a 
class of β-lactams with a broad-spectrum of antibacterial activity, have then widely been 
used as the mainstay for treatment of infections caused by such antibiotic resistant strains 
[24]. Unsurprisingly, Acinetobacter strains resistant to carbapenems have also rapidly 
emerged worldwide [24]. Different levels and patterns of antimicrobial susceptibilities 
have been found among different Acinetobacter species with several studies reporting a 
higher occurrence of multidrug resistance in A. baumannii compared with the non-A. 
baumannii species [59, 64, 65]. Furthermore, intra-species diversity of antimicrobial 
susceptibilities has also been reported with specific genotypes in the A. baumannii 
population demonstrating higher resistance rates to antimicrobial agents compared with 
other A. baumannii genotypes [61].  
 
It is important to mention that incorrect or uncertain species identification has probably 
resulted in an inaccurately-reported occurrence of some resistance genes in specific 
Acinetobacter species. A study conducted in 1992 reported the characterization of an 
AmpC cephalosporinase produced by A. calcoaceticus strain CCM 5593 [66]. However, 
strain CCM 5593 actually belongs to A. baumannii according to the LMG catalogue 
provided by the Laboratory of Microbiology at University of Gent in Belgium 
(http://bccm.belspo.be/db/lmg_search_form.php). A study from USA reported the 
occurrence of blaTEM, blaSHV, and blaADC genes in an A. pittii isolate (AG073) and an A. 
johnsonii isolate (AJ075) [55]. However, the two isolates were found to contain the A. 
baumannii-intrinsic blaOXA-51-like gene which could probably imply uncertain species 
identification [28].  
 
IMP-4 was reported to occur in an A. junii isolate [67]. However, the study used VITEK 
GNI card and API 20NE for species identification and these systems have repeatedly 
been associated with incorrect species identification of Acinetobacter isolates [24]. 
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blaADC might similarly be present in the chromosome of A. lwoffii although the species 
identification of the isolates was uncertain [68]. Furthermore, a recent review reported the 
occurrence of blaCTX-M-43 in A. baumannii although the original article referred to the 
isolates as Acinetobacter spp. [2, 69]. 
 
 
1.7.1. Intrinsic resistance 
 
Intrinsic resistance is defined as the inherent (not acquired) resistance against an 
antimicrobial drug which is a characteristic of all or almost all representatives of the 
species (http://www.eucast.org/expert_rules/). The antimicrobial activity of the drug is 
accordingly insufficient and the drug is clinically inadequate 
(http://www.eucast.org/expert_rules/). Consequently, antimicrobial susceptibility testing 
against the drug is unnecessary (http://www.eucast.org/expert_rules/). In this regard, A. 
baumannii and A. calcoaceticus are intrinsically resistant to ampicillin, amoxicillin-
clavulanate, cefazolin, cefotaxime, ceftriaxone, ertapenem, trimethoprim, and fosfomycin 
according to the expert rules in antimicrobial susceptibility testing of the European 
committee on antimicrobial susceptibility testing (EUCAST) 
(http://www.eucast.org/expert_rules/). Due to the activity of sulbactam, A. baumannii 




1.7.2. Resistance to ß-lactams 
 
Resistance to β-lactams in Acinetobacter involves: (i) the production of β-lactamases, (ii) 
alterations in the affinity to penicillin-binding proteins, (iii) decreased permeability of the 
outer membrane due to changes in the structure or number of porin proteins, and (iv) 






Figure 2. Mechanisms of β-lactam resistance. Acinetobacter, like other gram-negative bacteria, has an 
outer membrane and a cytoplasmic membrane, between which (the periplasmic space) β-lactamases 
(carbapenemases, AmpC β-lactamases, and extended-spectrum β-lactamases) reside. Penicillin-binding 
proteins (PBPs), located at the level of the cytoplasmic membrane, constitute the final targets of β-lactam 
antibiotics. To bind to these targets, antibiotics must traverse the outer membrane through porin channels 
(outer-membrane proteins) into the periplasmic space. Once in the periplasmic space, β-lactam antibiotics 
bind to PBPs or are actively expelled from the bacterial structure through efflux pumps. Acinetobacter can 
harbor integrons and transposons, genetic elements on the bacterial chromosome or on plasmids, that can 
carry multiple cassettes with resistant genes (e.g., extended-spectrum β-lactamases and metallo-β-
lactamases) (reproduced from reference [70] with permission from The New England Journal of Medicine). 
 
 
The over-expression of intrinsic and/or the horizontal obtaining of acquired β-lactamase 
genes encoding enzymes from the four different molecular classes (A-D) is the main 
mechanism of Acinetobacter resistance to β-lactams [70, 71]. A wide range of class A β-
lactamases including the narrow-spectrum (TEM-1, TEM-2, CARB-5, and SCO-1), 
extended-spectrum (TEM-92, TEM-116, SHV-2, SHV-5, SHV-12, CTX-M-2, CTX-M-3, 
CTX-M-43, PER-1, PER-2, PER-6, VEB-1, VEB-1a, VEB-3, GES-11, and GES-12), and 
carbapenem-hydrolyzing (GES-14, KPC-2, KPC-3, KPC-4 and KPC-10) variants have 
been identified mainly in A. baumannii but also among Acinetobacter isolates from other 
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species [24, 69, 72-77]. Class A β-lactamase genes are generally considered to be less 
widespread among Acinetobacter than Enterobacteriaceae species [71]. However, 
assessment of the true prevalence of extended-spectrum class A β-lactamases in 
Acinetobacter might be underestimated since it has been hindered by difficulties with 
laboratory detection, especially in the presence of intrinsic AmpC enzymes [2, 78].  
 
Class B β-lactamases (metallo-β-lactamases, MBLs) confer high levels of carbapenem 
resistance as well as resistance to all other ß-lactams except for aztreonam [79]. MBLs 
are characterized from other classes of β-lactamases by being susceptible to EDTA 
inhibition due to the requirement of zinc ions (Zn+2) in the active site [79]. Several IMP 
(IMP-1, IMP-2, IMP-4, IMP-5, IMP-6, IMP-8, IMP-11) and VIM (VIM-1, VIM-2, VIM-
4, and VIM-11) variants have been detected among isolates from the A. baumannii-A. 
calcoaceticus complex [57, 73, 79-82]. SIM-1 was first described in A. baumannii 
isolates from Korea [83]. The study reported a lower level of carbapenem resistance 
conferred by SIM-1 compared with that conferred by IMP and VIM variants [83]. To my 
knowledge, blaSIM-1-like genes have so far been found only among Acinetobacter isolates 
from Korea [83-85]. All different variants of blaIMP, blaVIM, and blaSIM in A. baumannii 
isolates have regularly been located on class 1 integrons [79]. NDM-1 has mainly been 
found in Enterobacteriaceae isolates particularly from the Indian subcontinent but has 
also been detected in A. baumannii isolates from India as well as from other parts of the 
world [86-88]. Interestingly, resistance to carbapenems mediated by the coexistence of 
blaNDM-1, blaOXA23, and blaIMP has been detected in pan-drug resistant A. baumannii 
isolates from China [88]. NDM-2, a variant of NDM-1 with only one amino acid 
substitution, has recently been described in an A. baumannii isolate recovered from a 
patient transferred to Germany from Egypt [89]. 
 
Class C β-lactamases (AmpC cephalosporinases) are enzymes able, when over-expressed, 
to hydrolyze most penicillins, cephalothin, cefazolin, cefoxitin, ceftazidime and ß-
lactamase inhibitor/ß-lactam combinations, but generally not cefepime or carbapenems 
[90]. So far, the chromosomal-encoded AmpC cephalosporinase genes have only been 
identified in a few Acinetobacter species (A. baumannii, A. pittii, and A. baylyi) [54, 90]. 
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Phylogenetic analysis demonstrated that AmpC cephalosporinases from A. baumannii 
and A. pittii are more closely related to each other than to the variants produced by other 
genera of bacteria [91]. Accordingly, these enzymes represent a distinct family of class C 
β-lactamases called “the Acinetobacter-derived cephalosporinases (ADCs)”. Although 
the AmpC cephalosporinase from A. baylyi (designated as ADC-8) was considerably less 
homologous to ADC-5 from A. pittii and ADC-7 from A. baumannii, the phylogenetic 
proximity of all the ADC cephalosporinases, including ADC-8, appeared to evolve from 
a common ancestor [92]. The blaADC genes in A. baumannii are normally expressed at 
basal levels [90]. The key factor for high levels of expression of these genes is based on 
the presence of a strong promoter within an upstream insertion sequence known as 
ISAba1 [90].  ADC enzymes are the main mechanism responsible for resistance to 
ceftazidime and other extended-spectrum cephalosporins in A. baumannii [55]. To date, 
at least 44 blaADC genes have been identified [73].  
 
Class D β-lactamases (OXA-type β-lactamases) are robust penicillinases given that all of 
them are able to significantly hydrolyze aminopenicillins (e.g. ampicillin and amoxicillin) 
and carboxypenicillins (e.g. carbencillin and ticarcillin) [93]. Some of the OXA-type β-
lactamase variants also have the ability to hydrolyze extended-spectrum cephalosporins 
whereas other variants, described as OXA-type carbapenemases, are able to hydrolyze 
carbapenems [93]. Most of the extended-spectrum OXA-type β-lactamases are basically 
point mutation derivatives of related narrow-spectrum enzymes while all the so far 
identified OXA-type carbapenemases are remotely related to the non-carbapenem-
hydrolysing OXA-type β-lactamases [93, 94]. OXA-20, OXA-21 and OXA-37 are the 
only narrow-spectrum OXA-type β-lactamases that have so far been identified in 
Acinetobacter isolates (A. baumannii) [93]. The genes for these three enzymes have been 
identified in the form of gene cassettes inserted into class 1 integrons [93]. None of the 
extended-spectrum OXA-type β-lactamases has yet been found in any Acinetobacter 
species [93]. In contrast, OXA-type carbapenemases, with the exception of blaOXA-48, 
have almost exclusively been found among isolates of the genus Acinetobacter (several 




The OXA-type carbapenemase genes in Acinetobacter spp. can be divided into four 
phylogenetic subgroups of (blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, and blaOXA-58-like) plus 
five discrete genes (blaOXA-134, blaOXA-104, blaOXA-143, blaOXA-164, and blaOXA-182) (Figure 
3). The variants within each of the four main subgroups have nucleotide sequence 
identities of ≥ 96% whereas the nucleotide sequence identities of the variants from 
different subgroups, including the discrete genes, range from 46% to 76% (Table 5). 
Exceptions include a 92% nucleotide sequence identity between blaOXA-143 and blaOXA-182 
and ~88% nucleotide sequence identity between blaOXA-24-like subgroup with either 
blaOXA-143 or blaOXA-182 (Table 5). 
 
The substrate profiles of OXA-type carbapenemases are diverse with most of them 
showing only a low hydrolytic activity against imipenem and yet a lower hydrolytic 
activity against meropenem [94]. The OXA-type carbapenemases additionally hydrolyse 
the narrow-spectrum penicillins (e.g. benzylpenicillin, ampicillin, piperacillin, ticarcillin) 
and cephalosporins (e.g. cefalotin and cefaloridine) efficiently. On the other hand, the 
extended-spectrum ß-lactams (e.g. ceftazidime, cefotaxime) and aztreonam are not or 
only very poorly hydrolyzed by these enzymes [94]. It is worth mentioning that the 
occurrence of OXA-type carbapenemase genes in Acinetobacter spp. represents vertical 
inheritance in specific species but horizontal acquisition in other species. The subgroup 
blaOXA-23-like for instance is intrinsically present and chromosomally located in A. 
radioresistens while it is acquired and most likely plasmid mediated in A. baumannii. 
The subgroup blaOXA-51-like and the variant blaOXA-134 are intrinsically present in A. 
baumannii and A. lwoffii, respectively. 
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Table 5. Nucleotide sequence identities among the OXA-type carbapenemase subgroups and discrete genes 






















60-64% 67-69% 67-68% 75-76% 59-61% 49-53% 63-65% 61-63% 96-100% 
blaOXA-
23-like 
63-64% 69-70% 68-69% 61-62% 65-66% 49-52% 69-71% 96-100%  
blaOXA-
24-like 
62-63% 87-88% 87% 64% 64-65% 51% 97-100%   
blaOXA-
58-like 
49% 51% 53% 46-47% 53% 97-100%    
blaOXA-
134 
66% 65% 63% 67% 100%     
blaOXA-
104 
60% 62% 62% 100%      
blaOXA-
143 
64% 92% 100%       
blaOXA-
182 
67% 100%        
blaOXA-
164 






Figure 3. Dendrogram of 90 OXA-type carbapenemase genes identified in Acinetobacter spp. obtained 
using the online multiple sequence alignment program ClustalW. Branch lengths are to scale and 
proportional to the number of amino acid changes. The distance along the vertical axis has no significance.  
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1.7.3. Resistance to aminoglycosides 
 
Enzymatic modification of aminoglycosides by acetyltransferases, nucleotidyltransferases 
and/or phosphotransferases accounts for the majority of aminoglycoside-resistant 
Acinetobacter isolates [99]. Several aminoglycoside-modifying enzymes have been 
detected in different Acinetobacter species (A. baumannii, A. pittii, A. nosocomialis, and 
A. johnsonii), including: (i) the phosphotransferases APH(3')-Ia, APH(3')-VIa, APH(3')-II 
(encoded by aphA1, aphA6, aphA15, respectively), (ii) the acetyltransferases AAC(3)-Ia, 
AAC(3)-IIa, AAC(6')-Ib, AAC(6')-Iad, AAC(6')-Im, and  AAC(6')-II (encoded by aacC1, 
aacC2, aacA4, aac(6')-Iad, aac(6')-Im, and aac(6')-II, respectively), and (iii) the 
nucleotidyltransferases ANT(2'')-Ia, ANT(3'')-Ia, and ANT(3'')-Id (encoded by aadB, 
aadA1, and aadA4, respectively) [25, 73, 99-102].  
 
The occurrence of a combination of two or more of aminoglycoside-modifying resistance 
genes and the association of some of these genes (such as aacC1, aacA4, aadA1 and 
aadB) with class 1 integrons has been reported [99]. Nonetheless, reduction of 
accumulation of aminoglycosides is also fairly common in Acinetobacter isolates [71]. 
Lately, A. baumannii strains producing the 16S rRNA methylase ArmA enzyme have 
been identified [103]. ArmA is plasmid-encoded and characterized by conferring a high-
level of pan-aminoglycoside resistance compared with a usually moderate-level of 
resistance against particular aminoglycosides resulting from production of the previously 
mentioned aminoglycoside-modifying enzymes [102]. The coexistence of armA with two 
carbapenem resistance genes, blaOXA-23 and blaNDM-1, has recently been reported in three 
clinical isolates from India [86]. 
 
 
1.7.4. Resistance to quinolones 
 
Resistance to quinolones in Acinetobacter species is mostly due to chromosomal 
mutations in the quinolone resistance determining region (QRDR) of the gyrA and parC 
genes with the subsequent production of modified bacterial DNA gyrase and 
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topoisomerase IV enzymes [71]. Ser-83 and Ser-80 in GyrA and ParC, respectively, are 
the most frequently mutated amino acid residues in quinolone-resistant A. baumannii 
(Table 6) [104, 105]. A double mutation in the QRDRs of both GyrA and ParC is 
basically necessary to obtain high levels of quinolone resistance [105]. Nonetheless, 
quinolone resistance could also be due to decreased influx and/or increased efflux of 
quinolones [71]. Of note, plasmid-mediated quinolone resistance genes, including 
aac(6’)-Ib-cr and qnr, have so far been not identified in Acinetobacter isolates [106].  
 
Table 6. Amino acid substitutions in the quinolone resistance determining region (QRDR) of gyrA and 
parC implicated in quinolone resistance in A. baumannii  
Amino acid substitutions Reference 
GyrA  
Gly-81 substituted by Val or Cys [104, 107] 
Ser-83a substituted by Leu [104] 
Ala-84 substituted by Pro [104] 
Glu-87 substituted by Gly [108] 
ParC  
Gly-78 substituted by Cys [107] 
Ser-80a substituted by Leu, Phe or Trp [105, 108, 109] 
Glu-84 substituted by Lys [105] 
aMutations Ser-83 to Leu in GyrA and Ser-80 to Leu in ParC were also reported in quinolone-resistant 




1.7.5. Role of ISAba elements  
 
Insertion sequences (IS) are the smallest (< 2.5 kb) and most abundant genetic elements 
capable of independent mobility (transposition) in microbial genomes [110]. IS elements 
can be responsible for the occurrence of insertion mutations, genome rearrangements, and 
enhanced spread of resistance and virulence determinants within species [110]. Several IS 
elements have commonly and probably exclusively been detected in the genus 
Acinetobacter (Table 7) (http://www-is.biotoul.fr) [111]. 
 
Studies have demonstrated the role of ISAba1 in providing a strong promoter resulting in 
over-expression of the intrinsic blaADC and blaOXA-51-like and the acquired blaOXA-23-like 
genes of A. baumannii [112-114]. ISAba1 most probably acts similarly with other 
resistance genes such as sulI1 and blaOXA-58-like, [111, 115]. ISAba2, ISAba3, IS18, and 
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ISAba825 might also provide strong hybrid promoters for blaOXA-58-like whereas ISAba4 
may likewise be responsible for an enhanced expression of blaOXA-23-like [114-116]. 
Furthermore, sequence analysis of the genetic environment of blaNDM-1 in one A. 
baumannii isolate from Germany revealed a chromosomal occurrence of blaNDM-1 on a 
10.5 kb genetic structure bracketed by two copies of ISAba125 [117]. The upstream 
ISAba125 element most likely provides a strong promoter for blaNDM-1 expression [118]. 
Interestingly, the blaADC gene in the fully sequenced A. baumannii strain ACICU is also 
preceded by an ISAba125 element that could influence its expression [119]. 
 
ISAba1 might also be responsible for the mobility of blaOXA-23-like with either two copies 
bracketing the gene and forming a composite transposon defined as Tn2006 or a single 
copy located at one side of the gene and forming a one-ended transposon defined as 
Tn2008 [106, 114]. Similarly, a single copy of ISAba4 located at one side of blaOXA-23-like 
might mobilize it by forming a one-ended transposon defined as Tn2007 [114]. An 
ISAba1-mediated disruption of the adeS gene which regulates the expression of the 
multidrug AdeABC efflux pump was detected in two tigecycline-resistant isolates [120]. 
The insertional inactivation of adeS was probably responsible for a constitutive over-
expression of the pump leading to increased resistance to various classes of antibiotics. 
Furthermore, ISAba825 and ISAba125 have been found responsible for reduced 
susceptibility to carbapenems by means of a natural insertional inactivation of the carO 
gene encoding an outer membrane channel associated with the influx of carbapenems A. 




Table 7. Insertion sequence (IS) elements in the genus Acinetobacter retrieved from the IS database 
homepage (http://www-is.biotoul.fr). 
Name Family GenBank accession 
number 
Origin 
ISAba1 IS4 AY758396 A. baumannii 
ISAba2 IS3 AY665723 A. baumannii 
ISAba3 IS1 AY665723 A. baumannii 
ISAba4 IS982 - A. baumannii 
ISAba5 IS5 - A. baumannii 
ISAba6 IS982 - A. baumannii 
ISAba7 IS5 - A. baumannii 
ISAba8 IS21 - A. baumannii 
ISAba9 IS982 - A. baumannii 
ISAba10 IS5 GQ379223 A. baumannii 
ISAba11 IS701 CP000521 A. baumannii 
ISAba12 IS5 - A. baumannii 
ISAba13 (ISN1) IS5 NC_011586 A. baumannii 
ISAba125 IS30 AY751533 A. baumannii 
ISAba825 IS982 AY751532 A. baumannii 
ISAca1 IS3 AF121266 A. calcoaceticus 
IS1008 IS6 AJ251307 A. calcoaceticus 
IS1236 IS3 U03772 A. calcoaceticus 
ISAha1 IS5 - A. haemolyticus 
ISAha2 IS5 - A. haemolyticus 
IS17 IS5 U95013 A. haemolyticus 
ISAjo1 IS5 - A. johnsonii 
ISAlw1 IS5 - A. lwoffii 
IS1006 IS6 NC_004361 A. junii 
ISAcsp1 Tn3 - Acinetobacter sp. 
IS1007 IS6 AJ250860 Acinetobacter sp. LS56-7 




1.8. Epidemiology of A. baumannii 
 
Among the different Acinetobacter species, A. baumannii has a remarkable ability to 
cause outbreaks of infections [24]. The occurrence of intra-hospital, local inter-hospital, 
and national A. baumannii outbreaks of infections have been reported worldwide [2]. 
Comparative typing of outbreak strains from geographically scattered European hospitals 
has demonstrated the occurrence of three extremely successful clones of A. baumanni 
named as “European clones I, II and III” [122, 123]. The three European clones have later 
on been found to disseminate globally and have accordingly been re-named as 
“international clones I, II and III” [39]. A significant shift towards international clone II, 
rather than international clone I, has lately been detected in the global A. baumannii 
population structure [124]. Multidrug resistance has been a frequent feature of the three 
clones although these clones have included strains with notable variations in their 
susceptibility patterns and underlying resistance genes [124]. However, a wide 
geographic distribution of several other clones, beyond international clones I to III, has 
also been detected [39, 125-127]. These clones have most likely played a supplementary 
role in the global dissemination of A. baumannii infections [39]. 
 
 
1.8.1. Molecular strain typing methods 
 
Several molecular methods have been used to type A. baumannii strains at different 
scales [24]. A PCR-based typing scheme targeting three genes under selective pressure 
(ompA, csuE and blaOXA-51-like) is a convenient method for rapid assorting of A. baumannii 
isolates into three major sequence groups (SG) corresponding to the previously 
mentioned international clones I (SG2), II (SG1), and III (SG3) [128]. Isolates can also be 
assigned into additional PCR-based sequence groups (SG4-SG7, putative SG8, SG9, and 
putative SG10-SG13) defined according to new combinations of the PCR amplicons 
(Table 8) (Papers II and III) [126, 129, 130]. Of note, the labels proposed for the PCR-
based SGs don't correspond to the labels proposed by another typing approach based on 
comparitive sequence analysis of the same three genes [126, 127, 129].  
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Table 8. Sequence groups of A. baumannii defined according to combinations of amplicons in two 
multiplex PCRs targeting the ompA, csuE and blaOXA-51-like genes.  
PCR-based sequence 
group (SG) 














SG1 (international clone II) + + + - - - [128] 
SG2 (international clone I) - - - + + + [128] 
SG3 (international clone III) + + - - + - [128] 
SG4  - + + - - - [126] 
SG5  - - + - - - [126] 
SG6  + - - - + + [126] 
SG7  - - + + - - [126] 
SG8a - + + + - - [129] 
SG9 - - + + - + Paper II 
SG10 - + - + + - [130] 
SG11 - - - - + + [130] 
SG12 - + - - - - Paper III 
SG13 + - + - - - Paper III 
aAssigned into group 6 according to the 3 locus sequence-based typing approach. 
 
Sequence-based analysis of only the blaOXA-51-like gene can also be a useful typing method 
for A. baumannii isolates since evident correlation has been detected between particular 
blaOXA-51-like variants and particular epidemic lineages [131, 132]. In this regard, a study 
conducted on sixty A. baumannii isolates collected worldwide has demonstrated that 
isolates belonging to international clone II encoded blaOXA-51-like variants from the OXA-
66 cluster while those belonging to international clone I encoded enzymes from the 
OXA-69 cluster [131, 132]. Furthermore, the study has shown that all isolates belonging 
to international clone III encoded blaOXA-71 standing by itself without forming a cluster 
with other variants [131, 132].  
 
Nevertheless, pulsed-field gel electrophoresis (PFGE) is still considered to be the `gold 
standard` for fine-scale typing of A. baumannii isolates [131]. PFGE, based on the 
generation of distinct patterns of chromosomal DNA, is able to detect the intra- and inter-
hospital bacterial transmission providing a method especially suited for local short-term 
outbreak investigations [133]. However, it has a main disadvantage that data are hardly 
exchangeable among laboratories making it inappropriate for comparative 
epidemiological analyses of results obtained at different laboratories [133]. On the other 
hand, multilocus sequence typing (MLST), based on the comparative sequence analyses 
of loci from seven house-keeping genes, offers the possibility to transfer typing data 
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between laboratories and via the internet, making it an appropriate technique for global 
and long-term epidemiological studies [131].   
 
Currently, two Acinetobacter MLST schemes are available for typing of A. baumannii 
strains. The Bartual scheme (http://pubmlst.org/abaumannii/) is based on DNA sequence 
comparisons of the internal fragments of seven housekeeping genes (gltA, gyrB, gdhB, 
recA, cpn60, gpi, and rpoD) [133]. However, analysis of gyrB and gpi sequences should 
be performed with caution since the phylogenetic trees generated for these two genes 
showed evidence of recombination and were inconsistent with those of the other five 
genes [131]. Similarly, the Pasteur scheme 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/) is based on DNA sequence 
comparisons of the internal fragments of seven housekeeping genes including three genes 
from the Bartual scheme (gltA, recA, and cpn60) plus four other genes (fusA, pyrG, rpoB, 
and rplB) [39]. The two schemes have generally showed compatible results although a 
recent study has reported a higher resolution of the Bartual MLST scheme providing a 
better association between epidemiological features, occurrence of acquired OXA genes, 
and temporal distribution of the isolates [134-136]. 
 
In general, PFGE and MLST should be considered as complementary tools to each other 
in epidemiological studies [137]. PFGE has a higher discriminatory power for small-sized 
local epidemiological studies while MLST has a better capability for grouping isolates 
mainly during large-sized global epidemiological analyses. 
 
 
1.8.2. Epidemiological terminology 
 
The definition of some terms, such as strain and clone, has repeatedly been discussed by 
epidemiological reviews [138]. For example, an isolate represents a general term used to 
describe a pure culture of bacteria, usually obtained by sub-culturing a single colony from 
a preliminary isolation plate, while a strain is a taxonomic term used to describe a 
subdivision of a species [139]. A strain can be defined as an isolate or group of isolates 
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that can be distinguished from other isolates of the same species by a number of 
phenotypic and/or genotypic characteristics [139]. An outbreak strain is a strain 
responsible for the occurrence of an outbreak of infections (an increased incidence of 
infections in a specific place during a given period that is above the baseline rate for that 
place and time frame) [139]. An outbreak strain will accordingly represent a group of 
epidemiologically, genotypically, and phenotypically related isolates [139]. Such isolates 
(outbreak isolates) are assumed to be a progeny of a recent single common precursor 
isolate.  
 
Since PFGE is considered to be the `gold standard` for outbreak investigations, an 
outbreak strain can molecularly be defined as a group of isolates obtained within a 
limited time and place frames that show identical or related pulsotypes (PFGE restriction 
patterns). Currently, similarities among pulsotypes are usually determined using the 
band-based Dice coefficient. However, optimum settings for optimization and tolerance 
have not yet been agreed on. Cluster analysis of pulsotypes is commonly performed using 
the unweighted pair group method with mathematical averaging (UPGMA). A cut-off 
level of 90% can be proposed for strain delineation [140].  
 
On the other hand, a clone is a group of epidemiologically unrelated (independently 
obtained from different sources, in different locations, and perhaps at different times) but 
genotypically and phenotypically related isolates [141]. Such isolates (epidemic isolates) 
are believed to be progeny of an old single common precursor isolate. Since MLST is the 
main tool for global population studies, a clone will practically be defined as a group of 
isolates obtained from more than one country and belong to one MLST sequence type or 
clonal complex. The occurrence in at least two countries is subjectively chosen to 
minimize the probability of a recent inter-hospital spread either by a direct patient 
transfer or by an intermediate circulation in the community [122]. The definition could be 
biased since it does not take into consideration the countries’ size or the occurrence of 
import. Nonetheless, the occurrence of import should always be highlighted (Papers II 
and III). Of note, a clonal complex (CC) is a group of related sequence types (ST) sharing 
alleles at 5/7 or 6/7 of the loci (http://eburst.mlst.net/v3/instructions/2.asp). The terms 
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“clonal complex” and “clone” are not interchangeable; a clonal complex represents a 




1.8.3. Proposed nomenclature 
 
The nomenclature of A. baumannii outbreak strains should probably include the time and 
place of occurrence and the pulsotype. Further phenotypic and/or genotypic 
characterization of the strain can then be used in order to describe the outbreak strain. For 
instance, outbreak strains can be designated as MDR- (for multidrug-resistance), blaOXA-
24-like-CR- (for blaOXA-24-like-positive carbapenem-resistance), Tn2006-blaOXA-23-like-CR- 
(for Tn2006-mediated blaOXA-23-like-positive carbapenem-resistance) etc. It could also be 
valuable to include the corresponding ST and CC in the description of A. baumannii 
outbreak strains in order to allow a comprehensive assignment of these strains in a global 
context [142].  
 
On the other hand, since the MLST allelic profiles are unambiguous and exchangeable, 
MLST provides an optimal naming system for A. baumannii clones rather than giving 
them roman numerals or letters [131]. The clones can be designated according to their 
STs and CCs together with their geographic distribution [39]. In contrast to outbreak 
strains, clones are believed to represent descendants of an old progenitor. Accordingly, 
the occurrence of broad intra-clonal diversity, with strains possessing a variety of 
phenotypic and genotypic resistance characteristics, can be anticipated [99]. Phenotypic 
and genotypic characterization of the clones could therefore be less essential than that of 
the outbreak strains. The higher discriminatory power of PFGE can also be exploited in 
the characterization of clones and probably the identification of sub-clones. However, 






1.8.4. MLST-based global population of A. baumannii  
 
Analysis of a subset of 441 A. baumannii isolates, selected from other studies and from 
the MLST databases, might facilitate making an unbiased overview of the current 
structure of the global A. baumannii population [39, 60, 61, 72, 82, 127, 130, 131, 133-
137, 142-146] (Papers II and III) (http://www.pasteur.fr/recherche/genopole/PF8/mlst/) 
(http://pubmlst.org/abaumannii/). The selection included one isolate per country per ST 
(geographically and genotypically divergent isolates) while other isolates from the same 
country with the same ST were rather considered as replicates of an outbreak strain and 
were excluded regardless if they were divergent by date of isolation or by their 
phenotypic and genotypic resistance characteristics. STs were grouped into CCs using 
eBURST V3 (http://eburst.mlst.net/) under stringent parameters (6/7 shared allels). 
However, an ST or CC would subjectively represent a clone only if included isolates 
from more than one country. 
 
The collection included isolates typed using the Bartual’s scheme (n=277), Pasteur’s 
scheme (n=129), or both schemes (n=35) (Tables S1-S3). To differentiate between the 
two MLST schemes, STs and CCs were designated as STB/CCB for the Bartual scheme 
and STP/CCP for the Pasteur scheme. The isolates belonged to 246 Bartual’s STs (ST1-
88B, ST90-110B, ST112-187B, ST189-197B, ST200B, and ST202-252B) and 83 Pasteur’s 
STs (ST1-32P, ST34-59P, ST77-86P, ST94-106P, ST109P, and ST110P) 
(http://pubmlst.org/abaumannii/) (http://www.pasteur.fr/recherche/genopole/PF8/mlst/).  
 
Overall, the analysis assigned 243/441 of the isolates into 22 clones including sixteen 
international (≥two continents) clones, five European clones, and one Asian clone (Table 
9) (Table 9 and Figures 4 and 5). On the other hand, 198/441 of the isolates were 






1.8.4.1. International clone CC92B/CC2P 
 
CC92B/CC2P was by far the largest A. baumannii clone with 88/441 of the isolates and a 
very broad international spread over 32 countries (Italy, Spain, Germany, UK, Greece, 
The Netherlands, Denmark, Czech Republic, France, Poland, Turkey, Norway, Sweden, 
Portugal, Ireland, Japan, China, Korea, Thailand, India, Malaysia, Philippines, Taiwan, 
Singapore, Vietnam, Lebanon, Brazil, South Africa, Reunion, Tahiti, New Caledonia, 
USA, and Australia). The Norwegian isolates were associated with import from other 
European or Asian countries (Paper II). CC92B/CC2P mainly included outbreak, MDR, 
and/or carbapenem-resistant (blaVIM-1-, blaOXA-23-like-, blaOXA-24-like-, and/or blaOXA-58-like-
encoding) isolates. It also included several isolates producing the 16S rRNA methylase 
ArmA enzyme and one isolate resistant to colistin. Interestingly, an equine isolate was 
found to belong to this clone as well.  
 
The occurrence of ST92B isolates resistant to all antimicrobial agents available including 
colistin, polymyxin B, and tigecycline was also reported by a study from Korea although 
the isolates have not been submitted into the MLST database [63]. The intra-clonal 
diversity of phenotypic and genotypic resistance characteristics among isolates of 
CC92B/CC2P is most likely due to the scattered spread of these clones throughout the 
world resulting in an access to a wide range of varied pools of transmissible resistance 
elements [99]. The analysis confirmed the linkage between CC92B/CC2P, international 
clone II, and the blaOXA-66, blaOXA-82, blaOXA-83, and blaOXA-109 variants (OXA-66 cluster) 
of the intrinsic blaOXA-51-like gene [131, 132].  
 
 
1.8.4.2. International clone CC109B/CC1P 
 
CC109B/CC1P was the second major A. baumannii clone with 51/441 of the isolates and a 
broad international spread over 29 countries (Germany, Italy, China, Libya, the United 
Arab Emirates, Bahrain, Norway, Argentina, India, Japan, Bulgaria, UK, Australia, 
Korea, Poland, Slovenia, Croatia, Czech Republic, Ireland, Belgium, South Africa, Spain, 
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France, USA, Greece, The Netherlands, Lebanon, Turkey, and Algeria). One isolate from 
UK and the two Norwegian isolates were associated with import from Pakistan and India 
(Paper II) [131, 132]. Similar to the previous clone, CC109B/CC1P also included many 
outbreak, MDR, and carbapenem-resistant (blaVIM-4-, blaOXA-23-like-, and/or blaOXA-58-like-
encoding) isolates.  
 
The clone was closely linked with international clone I and the blaOXA-69, blaOXA-107, 
blaOXA-110 and blaOXA-112 variants (OXA-69 cluster) [131, 132]. One isolate (K55-61) was 
assigned into CC1P by Pasteur’s scheme (ST94P) but represented a singleton (ST194B) 
rather than being a member of CC109B by Bartual’s scheme (Paper II). However, ST194B 
is a DLV of several STs from CC109B. Furthermore, this isolate interestingly contained 
blaOXA-69 but belonged to sequence group 9, instead of international clone I (Paper II). 
This might probably indicate that sequence group 9 represents a sub-group of 
international clone I. One isolate of ST248B (singleton) was reasonably found to encode 
blaOXA-92 from the OXA-69 cluster since ST248




1.8.4.3. International (South and North American) clone CC131B 
 
CC131B has so far been a South and North American clone with 18/441 of the isolates 
obtained from Argentina, Brazil, and USA. The clone included several hospital 
environmental isolates (personnel hand, cushion, bed-rail, soap dispenser etc.) 
(http://pubmlst.org/abaumannii/). A probable linkage could be present between CC131B 
and the singleton ST79P from the Pasteur’s scheme [130]. Interestingly, two of the 
CC131B isolates belonged to international clone II [130, 131]. The two isolates also 
encoded for blaOXA-66 and blaOXA-65 from the OXA-66 cluster [130, 131]. ST79
P and 
ST121B, a DLV of several STs from CC131B, included isolates recovered from Spain 
indicating that the distribution of this clone could probably be not restricted to South and 




1.8.4.4. International clone CC187B/CC3P 
 
CC187B/CC3P was an international clone with 12/441 of the isolates obtained mainly 
from European countries (France, Germany, Spain, The Netherlands, Italy, and Belgium) 
as well as from Lebanon. CC187B/CC3P was closely linked with international clone III 
and the blaOXA-71 variant of blaOXA-51-like genes [131, 132]. Many of the CC187
B/CC3P 
isolates were MDR and/or carbapenem-resistant (blaOXA-58-like-encoding) and were 
associated with outbreaks of infections. A canine isolate was assigned into ST13P which 
was found to be a DLV of ST3P. Of note, the less intra-clonal diversity within 




1.8.4.5. International clone CC104B/CC15P 
 
CC104B/CC15P, another international clone, included 12/441 of the isolates obtained 
from 8 countries in Europe and South America (Norway, Portugal, Czech Republic, The 
Netherlands, Turkey, Spain, Argentina, and Brazil). The Norwegian isolate was however 
associated with import from Pakistan (Paper II). This clone included outbreak, MDR, 
carbapenem resistant (blaOXA-23-like-and blaOXA-58-like-positive), and armA-encoding 
isolates. The analysis detected a linkage between CC104B/CC15P, PCR-based sequence 
group 4, and encoded the intrinsic blaOXA-51 and blaOXA-132 variants (Paper II) [130, 134]. 
Two isolates from ST249B and ST250B, DLVs of CC104B, were also found to encode the 
blaOXA-51 variant [131]. Of note, blaOXA-132 and blaOXA-51 are one nucleotide different 





1.8.4.6. Other clones 
 
The analysis also identified CC20B as another international clone with 10/441 of the 
isolates recovered from Germany, Morocco, South Africa, Malaysia, Korea and China. 
Interestingly, the clone included one blaOXA-23-like- and armA-encoding isolate [144]. In 
addition, another blaOXA-23-like- and armA-encoding isolate belonged to ST248
B which was 
found to be a DLV of ST20B [144]. Isolates from CC20B encoded the intrinsic blaOXA-51 
and blaOXA-68 variants. However, blaOXA-51 and blaOXA-68 did not belong to a one group of 
variants [132]. International clone CC110B included 5/435 of the isolates obtained from 
Korea, Argentina, and USA. Interestingly, the CC110B isolate from China was colistin 
resistant [144]. European clone CC32P included 5/441 of the isolates obtained from 
Sweden, Denmark, Spain, and Portugal. One of the CC32P isolates was blaIMP-5-positive 
carbapenem-resistant.  
 
Interestingly, clonal spread was also identified for a number of singleton STs (e. g. 
ST17B, ST19B, ST73B, ST184B, ST25P, and ST49P) [61]. This probably indicates a fast 
spread associated with limited time for these strains to genetically differentiate and create 
clonal complexes of many variants which might be a result of immaturity of these 
genotypes or due to a shortened life length possibly caused by an effective eradication. 
International clone ST73B included only two isolates (2/435) with one of them being 
blaOXA-23-like-positive carbapenem-resistant. International clone ST25
P included 6/441 of 
the isolates obtained from The Netherlands, Turkey, Greece, Italy, Sweden, and 
Singapore. The Swedish isolate was associated with import from Thailand (Paper III). 
Carbapenem resistance was prevalent in clone ST25P since 5/6 of the isolates were 
blaOXA-23-like-, blaOXA-58-like-, and/or blaOXA-24-like-positive carbapenem-resistant. Other 





1.8.4.7. Non-clonal STs and CCs  
 
A large fraction of the isolates (~45%) was assigned into STs or CCs geographically 
restricted to one country. Interestingly, several clonal complexes such as CC164B, 
CC(32/33/46/47)B, and CC(85/86)B etc. did not represent clones. For instance, CC164B 
could basically represent a Korean 2008 outbreak strain although it included 5 isolates 
from 5 different STs. Many STs were found to include sporadic (not associated with an 
outbreak) strains. However, a number of non-clonal STs, such as ST96B and ST78P, were 
found to include outbreak strains [127, 142]. ST12B included one isolate (RUH 875) from 
international clone I although RUH 875 was assigned into completly different ST by 
another study [39, 131-133]. Interestingly, non-epidemic ST2B and ST134B included 
isolates encoding the blaOXA-96 variant [130, 131, 133].  
 
The occurrence of isolates of international clone II within non-epidemic singleton 
ST252B and ST59P was unexpected. In contrast to what has previously been reported, 
ST59P and CC2P diverged by 4 or 5 of the seven allels [39]. Furthermore, blaOXA-108 
encoded by the ST252B isolate was also not related to the OXA-66 cluster [132]. This 
could probably indicate a long-termed descent from a single ancestor, lack in the 
discriminatory power of the PCR-based clonal lineage typing method, or occasional 
inaccuracy in experimental results.  
 
Finally, the identification of many singleton STs demonstrated a high genetic diversity of 
the population structure of A. baumannii [143]. Such broad diversity has previously been 






Figure 4. eBURST of 313 A. baumannii isolates investigated by the Bartual`s MLST scheme (Tables S1 
and S3). Each circle corresponds to one sequence type (ST). Circle size increases logarithmically with the 
number of isolates of each ST. Each line indicates that the connected circles correspond to STs sharing 6/7 
of the allels. Each group of circles linked by at least one line corresponds to one clonal complex (CC). 
Distance between circles does not correspond to the number of allelic mismatches among the corresponding 





Figure 5. eBURST of 129 A. baumannii isolates investigated by the Pasteur`s MLST scheme (Table S2). 
Each circle corresponds to one sequence type (ST). Circle size increases logarithmically with the number of 
isolates of each ST. Each line indicates that the connected circles correspond to STs sharing 6/7 of the 
allels. Each group of circles linked by at least one line corresponds to one clonal complex (CC). Distance 
between circles does not correspond to the number of allelic mismatches among the corresponding STs. 
Each circle or group of circles highlighted in red corresponds to one clone. 
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CC92B/CC2P International clone with 88 isolates recovered from 32 countries in Europe, Asia, 
Africa, Australia, North America, and South America 
CC109B/CC1P  International clone with 51 isolates  recovered from 29 countries in Europe, Asia, 
Africa, The Middle East, Australia, and South America 
CC131B South and North American clone with 18 isolates recovered from Argentina, Brazil, 
and USA 
CC187B/CC3P International clone with 12 isolates recovered from 6 European countries and Lebanon 
CC104B/CC15P International clone with 12 isolates obtained from 8 countries in Europe and South 
America (One isolate was exported from Pakistan) 
CC20B International clone with 10 isolates recovered from 7 countries in Europe, Asia, and 
Africa 
CC110B  International clone with 5 isolates recovered from Korea, Argentina, and USA 
CC32P European clone with 5 isolates recovered from Sweden, Denmark, Spain, and Portugal 
CC119B  International clone with 4 isolates recovered from Korea, Thailand, and Argentina 
CC69B International clone with 4 isolates recovered from Korea and Australia 
ST25P International clone with 6 isolates recovered from Europe and Asia 
CC10P International clone with 5 isolates recovered from 4 European countries and Australia 
CC(222/228/229)B  International clone with 3 isolates recovered from Brazil and Japan 
ST17B International clone with 3 isolates recovered from Germany, China, and Korea 
CC105P International clone with 3 isolates recovered from Czech Republic and China 
ST19B European clone with 2 isolates recovered from Germany and UK 
ST73B International clone with 2 isolates recovered from Australia and Korea 
ST184B Asian clone with 2 isolates recovered from China and Korea 
ST5P European clone with 2 isolates recovered from Poland and Swedenb 
CC(6/85)P European clone with 2 isolates recovered from UK and Greece 
CC(83/109)P European clone with 2 isolates recovered from Turkey and Swedenc 
ST49P International clone with 2 isolates recovered from The Netherlands and USA 
aCC110B and CC(222/228/229)B were DLVs of each other; CC69B and ST19B were DLVs of CC92B; ST49P 
was a DLV of ST3P  
bUSA, the United States of America; UK, the United Kingdom. 
cCould probably represent a polish outbreak-related or endemic strain since the isolate from Sweden was 
exported from Poland. 




2. Aims of the study 
 
 
The main aim of paper I was to determine the distribution of Acinetobacter species in a 
nation-wide collection of consecutive blood culture isolates from Norway.  
 
Papers II and III aimed to investigate the molecular epidemiology and antibiotic 
resistance characteristics of carbapenem-resistant clinical isolates of A. baumannii 
obtained in Norway and Sweden, respectively. 
 
Paper IV was designed to compare the performance of three commercial systems (VITEK 









A collection of 113 consecutive blood culture isolates of Acinetobacter species was 
included in paper I. The isolates were collected between 2005 and 2007 from 111 patients 
by 19 diagnostic microbiology laboratories throughout Norway. Four isolates recovered 
from two patients were included since they were found to belong to different species. 
 
Paper II included 11 carbapenem resistant A. baumannii clinical obtained between 2004 
and 2009 from 11 patients from different specimens (blood, pus, respiratory secretions, 
abdominal cavity fluid and spinal fluid) by six different diagnostic microbiology 
laboratories in Norway. The study included all the isolates submitted to the Reference 
Centre for Detection of Antimicrobial Resistance in Norway based on carbapenem 
resistance according to guidelines issued by the Reference Centre.  
 
Paper III included 13 A. baumannii clinical isolates collected between 2004 and 2007 
from 11 patients from different cultures (blood, pus, respiratory secretions, and 
abdominal cavity fluid) by two laboratories in Stockholm and Kalmar, Sweden. Three 
isolates recovered from one patient were included since they were found to belong to 
different epidemiological lineages. All isolates were non-susceptible to imipenem or 
meropenem according to SRGA (Swedish Reference Group for Antibiotics) disk 
diffusion methodology (http://www.srga.org/RAFMETOD/BASMET.HTM) and 
breakpoints (http://www.srga.org/ZONTAB/zontab2a.htm).  
 
Paper IV included 110/113 of the isolates described in paper I. Three isolates were 
excluded given that they were identified as ‘unclassified’ using partial rpoB sequence 
analysis (Paper I). 
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4. Main results 
 
 
Paper I  
 The study revealed that partial rpoB sequence analysis was able to correctly assign 
the majority of the isolates (110/113) into at least 12 different Acinetobacter species.  
 Molecular identification revealed that A. nosocomialis (46.9%) and A. pittii (19.5%) 
were the most prevalent Acinetobacter species whereas A. baumannii only accounted 
for 8.8% of the isolates. 
 The study represented the first report on the putative clinical relevance of A. soli. 
 Less than 5% of the isolates expressed reduced susceptibility to one or more of the 
antimicrobial agents. 
 blaOXA-23-like was detected in all three carbapenem-susceptible A. radioresistens 
isolates and in one carbapenem-resistant A. baumannii isolate. blaOXA-23-like was 
associates with an upstream ISAba1 element only in the A. baumannii isolate. 
 A novel mutation, Ser-80 to Tyr, in the QRDR of ParC was identified in one A. 
baumannii isolate showing high-level resistance to ciprofloxacin, levofloxacin and 
nalidixic acid. 
 
Paper II  
 The isolates belonged to CC2P/CC92B/international clone II (n=7), 
CC1P/ST194B/SG9 (n=2), CC1P/CC109B/international clone I (n=1), and 
ST15P/CC104B/SG4 (n=1). 
 Resistance to carpabenems was due the occurrence of acquired OXA-carbapenemase 
genes including: blaOXA-23-like (n=9), blaOXA-24-like (n=1), and blaOXA-58-like (n=1).  
 Analysis of the genetic environment of blaOXA-23-like revealed a putative occurrence of 
Tn2006 and Tn2008 in seven and one isolates, respectively.  
 High levels of aminoglycoside-resistance, detected in four isolates, were associated 
with identification of the 16S rRNA methylase armA gene. 
 Class 1 integrons with six different variable regions carrying various combinations of 




 The isolates belonged to ST2P/international clone II (n=6), ST23P/SG5 (n=2), 
ST25P/SG12 (n=2), ST5P/SG7 (n=1), and ST109P/SG13 (n=2).  
 Resistance to carpabenems was due the occurrence of acquired OXA-carbapenemase 
genes including: blaOXA-58-like (n=7), blaOXA-23-like (n=5), and blaOXA-24-like (n=1).  
 ISAba825 was detected upstream of blaOXA-58-like in two isolates.  
 None of the previously known IS elements were detected upstream of blaOXA-58-like in 
one isolate.  
 Class 1 integrons with three different variable regions carrying various combinations 
of six resistance genes were detected in six isolates.  
 
Paper IV 
 VITEK 2 correctly identified 9 A. baumannii and 3 A. lwoffii isolates to the species 
level. BD Phoenix correctly identified 5 A. baumannii isolates to the species level. On 
the other hand, MALDI-TOF MS correctly identified 22 A. pittii, 10 A. baumannii, 8 
A. lwoffii, 3 A. ursingii, 3 A. radioresistens, and 1 A. calcoaceticus isolates to the 
species level.  
 Only MALDI-TOF MS was able to distinguish isolates of A. pitti from those of A. 
baumannii. 












5.1. Species distribution in blood culture isolates from Norway 
 
A. baumannii has frequently been considered the most clinically relevant Acinetobacter 
species worldwide [24]. However, our study revealed that only 10/113 (8.8%) of the 
consecutive blood culture isolates of Acinetobacter species from Norway belonged to A. 
baumannii. The study showed that A. nosocomialis and A. pittii were the most 
predominant Acinetobacter species with 53/113 (46.9%) and 23/113 (19.5%) of the 
isolates, respectively (Paper I). A drawback of my study was the lack of clinical data on 
each case, including the separation between colonization and infection, determination of 
injury severity scores, utilization of mechanical ventilation and catheterization, 
application of antimicrobial therapy, and outcomes. 
 
The ability to persist on inanimate dry surfaces (humidifiers, hospital equipments, 
furniture, mattresses) and animate (human skin and mucus membranes) objects is 
probably a main factor in the long-term existence of particular Acinetobacter spp. in the 
hospital setting which subsequently results in a prolonged opportunity to infect patients 
[71]. However, although A. baumannii is the most prevalent Acinetobacter species in 
clinical samples, it is not the most prevalent Acinetobacter species in the hospital 
environment. A. radioresistens was more commonly detected than A. baumannii among 
environmental specimens obtained from pillows at one Dutch hospital [148]. Besides, A. 
pittii was more commonly detected than A. baumannii on the skin of patients and student 
nurses from Hong Kong [45]. A. lwoffii and A. johnsonii were the most commonly 
detected Acinetobacter species on skin and mucus membranes of inpatients and control 
non-hospitalized persons from Germany [43].  
 
A study from USA showed that among 87 A. baumannii clinical isolates, 61 isolates 
(70%) were associated with infection and only 26 isolates (30%) were associated with 
colonization whereas among 20 non-A. baumanni clinical isolates, only 2 isolates (10%) 
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were associated with infection and 18 isolates (90%) were associated with colonization 
[62]. Accodingly, A. baumannii probably demonstrates an increased ability to infect, 
rather than to colonize, and then to cause an outbreak of infections, compared to other 
Acinetobacter species [24, 62]. The explanation could basically be that A. baumannii is 
genotypically more able to infect a vulnerable patient (probably following a 
temporary/prolonged colonization of the patient’s gastrointestinal tracts) and then to 
cross-infect more patients (probably via a temporary/prolonged colonization of the hands 
of healthcare professionals or contamination of a medical device) compared to the non-A. 
baumannii species [24, 49].  
 
Therefore, in addition to the incorrect and uncertain species identification applied by 
some studies, the reason why many studies from different countries have repeatedly 
reported A. baumannii to be more prevalent in clinical speciemens than other 
Acinetobacter species could, in my opinion, be because these studies have included 
replicates of the same strain. A recent Dutch study revealed that A. baumannii was 
involved in one large cluster (32 isolates) and nine small clusters (2-5 isolates) of isolates 
whereas other species (A. ursingii, A. pittii, A. nosocomialis, A. berezinae, and A. 
beyerinckii) were all together involved in only seven small clusters (2-5 isolates) [64]. 
The study showed that A. baumannii would be more prevalent than A. pitti if all the 
isolates were included. However, A. baumannii would be as common as A. pitti if the 
large cluster of A. baumannii was not included. Furthermore, A. pitti would exceed A. 
baumannii in the number of isolates if the small clusters were not included.  
 
The limited contribution of A. baumannii in our collection of Acinetobacter blood culture 
isolates might therefore be due to (i) the presence of better conditions in the Norwegian 
clinical settings (less-crowded hospitals), (ii) the restricted use of antibiotics, and (iii) the 
application of more strict infection control regimes in Norway compared to other 
countries [149]. These factors will restrict the capacity of A. baumannii (more than other 
Acinetobacter species) to infect and cross-infect patients. Improvements in the health 
sector of some countries might, in my opinion, change the Acinetobacter species 
distribution in clinical isolates. However, epidemiological studies should, in my opinion, 
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never exclude replicate isolates as long as obtained from different patients since this 
would under-estimate the high ability of particular species (such as A. baumannii) to 
infect and cross-infect patients.  
 
 
5.2. Predominance of CC92B/CC2P/international clone II 
 
Analysis of the molecular epidemiology of A. baumannii clinical isolates obtained from 
Norway and Sweden yielded results consistent with other studies on the extensive 
distribution of CC92B/CC2P/international clone II worldwide (Papers II and III). Several 
factors and several approaches of evolution might be proposed to explain the 
predominance of this clone, and other clones, in the global population of A. baumannii 
(Figure 6). 
 
The occurrence of a successful spread for isolates of CC92B/CC2P/international clone II 
might be due to a large clonal spread of one recent ancestor. The theory has been 
supported by a study from Korea showing that all the carbapenem-resistant ST92B 
isolates obtained from five cities belonged to one outbreak pulsotype [144]. Furthermore, 
eight of nine carbapenem-resistant isolates of ST92B obtained from three continents 
showed related PFGE patterns [135]. The nation-wide and worldwide spread of isolates is 
probably provoked by the massive increase of international travel, including transfer of 
patients among different countries.  
 
On the other hand, the worldwide spread of CC92B/CC2P/international clone II could also 
be related to independent but parallel emergence of smaller clones expanding from 
several progenitors and probably one older ancestor. The carbapenem-resistant ST92B 
isolates obtained from 16 cities in China (n=72) were distributed among at least three 
outbreak pulsotypes [142]. Furthermore, a number of carbapenem-resistant ST92B 
isolates from China belonged to sporadic pulsotypes [144]. Similarly, distinct pulsotypes 
were assigned to isolates from the CC92B obtained in Norway (Paper II). The similarity 
in resistance traits and determinants among isolates of distinct pulsotypes (proposed to be 
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independently-emerging) could be due to comparable selection pressures in different 
parts of the world [99]. Of note, using PFGE data to compare the two theories might 
consider by some authors as a main drawback since PFGE may lose its discriminatory 
power when analyzing isolates from geographically diverse areas [131].  
 
One factor to explain the predominance of CC92B/CC2P/international clone II could be 
that specific genotypes probably have increased capacity for epidemic spread than other 
genotypes. In other words, particular strains are genotypically more able to spread than 
other strains. Nonetheless, the presence of determinants associated with increased 
capability of transmission, colonization, and/or invasion which may explain the epidemic 
behavior of these particular strains is so far unknown and has yet to be investigated [24].  
 
Acquisition of antibiotic-resistance mechanisms and the evolution from antibiotic-
susceptible to MDR- and carbapenem-resistant to pandrug-resistant 
CC92B/CC2P/international clone II is probably another essential factor in the 
predominance of CC92B/CC2P/international clone II. A. baumannii demonstrates a 
remarkable propensity to rapidly acquire resistance determinants to a wide range of 
antibacterial agents [150]. The acquisition of antimicrobial resistance determinants 
increases the ability of A. baumannii strains to survive in the hospital setting, providing 
them more time for dissemination and further clonal expansion [61]. CC92B isolates have 
frequently expressed higher resistance rates to all antimicrobial agents than the other 
genotypes [61]. However, it has not been investigated if particular genotypes (such as 
ST92B) have a higher ability to acquire resistance genes compared to other genotypes. 
 
The emergence of drug-resistant CC92B/CC2P/international clone II has most likely 
resulted from independent events of acquisition of various resistance determinants using 
different mobile elements [135]. Acquisition of blaOXA-23-like has, for instance, been a 
major mechanism of carbapenem-resistance in CC92B/CC2P/international clone II [144]. 
The identification of blaOXA-23-like in all A. radioresistens isolates has indicated intrinsic 
occurrence, and carbapenem-susceptible A. radioresistens has accordingly been proposed 
as the silent source of blaOXA-23-like-based carbapenem-resistance in other Acinetobacter 
61 
 
spp [151] (Paper I). However, the identification of different genetic structures 
surrounding blaOXA-23-like (e. g. transposons Tn2006 and Tn2008) indicates concurrent but 
independent events of acquisition of blaOXA-23-like, probably due to comparable selective 
pressures related to comparable increased carbapenem usage in different geographic areas 




Figure 6. Predominance of CC92B/CC2P/international clone II. Favorable genetic background and 
acquisition of foreign genes are proposed to be main factors for the emergence of particular strains with 
increased epidemicity than other strains. International travel and independent but parallel emergence are 
probable hypotheses for the extensive worldwide distribution. 
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5.3. Class 1 integrons in A. baumannii  
 
Integrons essentially consist of an integrase gene (intI) and an adjacent integration site 
(attI), together composing the 5` conserved segment (5`CS) [152] (Figure 7). In addition, 
class 1 integrons typically contain a combination of a truncated antiseptic-resistance gene 
(∆qacE), a sulfonamide-resistance gene (sulI), and an open reading frame of unknown 
function (orf5), together representing the 3` conserved segment (3`CS) [153]. A variable 
region of gene cassettes can then be situated between 5`CS and 3`CS [153]. Importantly, 
gene cassettes are mobilized by the integrase enzyme (IntI) while class 1 integrons by 




Figure 7. Outline of the process of integron-mediated insertion of a circular gene cassette. The integrase 
gene (intI) located in the 5` conserved ssegment (5`CS) encodes a site-specific recombinase enzyme (IntI). 
The Integrase mediates a recombination event between specific attachment sites (attI and attC). The 
inserted open reading frame (orf) is expressed by the strong promoter Pc located in the 5`CS. 
 
 
The ability of class 1 integrons to capture various gene cassettes involved in antibiotic 
resistance has significantly contributed to the dissemination of multidrug-resistant 
bacterial strains worldwide [154]. In addition, analysis of the geographic distribution of 
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class 1 integrons with particular variable regions might be important in detecting the 
emergence and pattern of spread of particular clones of bacteria [99]. One aim of papers 
II and III was to detect and charaterize class 1 integrons among 24 multidrug- and 
carbapenem-resistant A. baumannii isolates obtained in Norway and Sweden. Our study 
revealed the occurrence of class 1 integrons with eight different variable regions (Table 
10). Interestingly, particular class 1 integrons revealed a broad worldwide and multi-
clonal distribution whereas other class 1 integrons showed a relatively less extensive 
continent-limited geographical spread. 
 
Table 10. Class 1 integrons with 8 different variable regions detected in Papers II and III 
Variable region Isolate 
Country (import) and 
year of isolation 
Genetic background 
aacA4-orfO-blaOXA-20 K12-21 Norway (Greece), 2004 ST45
P/ST189B/int. clone II 
 AO-12066 (K51-54) Sweden (no import), 2004 ST2P/int. clone II 
 AO-12327 (K51-63) Sweden (Greece), 2005 ST2P/int. clone II 
 AO-15204 (K51-59) Sweden (Greece), 2006 ST2P/int. clone II 
 AO-8058 (K51-53) Sweden (Greece), 2007 ST2P/int. clone II 
aac(6’)-Im-aadA1 K44-35 Norway (Thailand), 2007 ST2P/ST190B/int. clone II 
aacC1-orfP-orfP-orfQ-aadA1 K47-42 Norway (China), 2007 ST2P/ST191B/int. clone II 
aacA4-catB8-aadA1 K47-42 Norway (China), 2007 ST2P/ST191B/int. clone II 
 K58-19 Norway (Italy), 2009 ST2P/ST118B/int. clone II 
aacC1-orfP-orfQ-aadA1 K48-42 Norway (India), 2008 ST1P/ST192B/int. clone I 
arr2-cmlA5 K71-71 Norway (Pakistan), 2009 ST15P/ST103B/SG4 
aadB-aadA1-IS AO-8866 (K51-58) Sweden (Poland), 2006 ST5P/SG7  




Class 1 integron with the variable region aacA4-orfO-blaOXA-20 was detected in five 
isolates obtained in Norway (n=1) and Sweden (n=4) (Papers II and III). Interestingly, all 
the five isolates belonged to international clone II. Furthermore, the Norwegian isolate 
and three of the Swedish isolates were associated with import from Greece. To my 
knowledge, the aacA4-orfO-blaOXA-20 variable region has so far been detected only in A. 
baumannii isolates (http://www.ncbi.nlm.nih.gov/genbank/) [99, 155-159]. Furthermore, 
it has exclusively been detected in isolates obtained from Europe (France, Italy, Spain, 
Norway, and Sweden) with a frequent occurrence in Greece [99, 155-159] (Papers II and 
III). Interestingly, the Greek and Italian isolates reported by Nemec et al. and D’Arezzo 
et al. were found to belong to international clone II as well [99, 159]. Whole-genome 
sequence analysis of an Italian MDR A. baumannii clinical isolate “ACICU”, also 
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belonging to international clone II, revealed an interesting occurrence of the aacA4-orfO-
blaOXA-20 variable region within a chromosomal resistance island designated as AbaR2 
[119].  
 
The identification of class 1 integron with aac(6’)-Im-aadA1 in a Norwegian isolate 
imported from Thailand (Southeast Asia) was, from a geographic point of view,  fairly 
consistent with previous studies reporting the occurrence of this integron in A. baumannii 
isolates from Korea (East Asia) (unpublished study, GenBank accession no: CP001921) 
[101] (Paper II). However, the aadA1 cassette was disrupted by IS26 in the Korean 
isolates. Of note, the variable region aac(6’)-Im-aadA1 has so far been detected only in 
A. baumannii isolates (http://www.ncbi.nlm.nih.gov/genbank/) [101] (Paper II). 
Interestingly, the Norwegian isolate (K44-35) belonged to international clone II 
indicating that geographical boundaries might be an important factor in the emergence of 
intra-clonal clusters of isolates (subclones) showing distinct genomic markers [99] (Paper 
II). 
 
On the other hand, results of our work extended the broad worldwide distribution 
(Australia, China, Malaysia, and many European countries) of class 1 integrons with the 
variable regions aacC1-orfP-orfP-orfQ-aadA1 and aacC1-orfP-orfQ-aadA1 among A. 
baumannii isolates of both international clones I and II [99, 153, 156-163] (Papers II and 
III). The variable region aacC1-orfP-orfQ-aadA1 was also found in an equine isolate 
obtained from Ireland [164]. Interestingly, the variable region aacC1-orfP-orfQ-aadA1 
has also been detected in Klebsiella pneumoniae (unpublished study, GenBank accession 
no: HM589045). Of note, the variable region aacC1-orfP-orfP-orfQ-aadA1 was located 
within the resistance islands AbaR1, AbaR5, and AbaR6 in A. baumannii strains AYE 
(France), 3208 (Australia) and D2 (Australia), respectively, whereas aacC1-orfP-orfQ-
aadA1 was situated in AbaR3 and AbaR7 in A. baumannii strains AB0057 (USA) and 
A92 (Australia), respectively [150, 165-167].  
 
The occurrence of these integrons in isolates from distinct clones and different worldwide 
locations indicates that these integrons are (i) remarkably stable, (ii) extremely valuable 
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for the host bacteria, and (iii) essential in the dissemination of particular antibiotic 
resistance genes [100]. Stability in this context refers to the occurrence of class 1 
integrons with conserved and stable variable regions [99]. In other words, it means that 
the resistance genes located in class 1 integrons are transferred as part of the entire 
integron structure more often than as individual gene cassettes [168].  
 
A scattered distribution (UK, Italy, and China) has been reported for class 1 integron with 
the variable region aacA4-catB8-aadA1 [160, 163, 169, 170] (Paper II). Similarly, a 
limited but dispersed distribution (Sweden, France, Turkey, Palestine, and Egypt) has 
been reported for class 1 integron with the variable region blaGES-11-aacA4-dfrA7 [75, 78, 
171] (Paper III). The aacA4-catB8-aadA1 variable region has also been identified in 
several other bacterial genera such as Enterobacter cloacae, Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Burkholderia cepacia (unpublished studies, 
GenBank accession no.: HM175870, HM175872, DQ141317, HM989924, and 
HQ880251, respectively), and Stenotrophomonas maltophilia [172] whereas the blaGES-
11-aacA4-dfrA7 variable region has so far been identified only in A. bamannii isolates 
(http://www.ncbi.nlm.nih.gov/genbank/) [75, 78, 171]. The occurrence of aacA4-catB8-
aadA1 in different host genera also indicates the remarkabe stability and extreme 
valuability of this integron [168]. However, the less geographic distribution in the A. 
baumannii global society is probably due to a recent acquisition of aacA4-catB8-aadA1 
compared to aacC1-orfP-orfP-orfQ-aadA1 and aacC1-orfP-orfQ-aadA1.  
 
Class 1 integron with the variable region aadB-aadA1-IS has not been reported before in 
A. baumannii isolates; it has previously been detected only in a swine E. coli isolate from 
Germany and on a plasmid recovered from a wastewater treatment plant [173, 174] 
(Paper III). To my knowledge, class 1 integron with the variable region arr2-cm1A5 with 
no other gene cassettes has been reported for the first time by our research group 
(http://www.ncbi.nlm.nih.gov/genbank/) (Paper II). The variable region arr2-cm1A5 has 
subsequently been detected in an A. baumannii isolate from Kenya (unpublished study, 




5.4. MALDI-TOF MS for precise Acinetobacter species identification  
 
The capability of MALDI-TOF MS to accomplish species identification in less than one 
hour makes it particularly suitable for routine clinical laboratories (4). Previously, species 
identification of 552 well-characterized Acinetobacter strains representing 15 different 
species using the MALDI-TOF MS system has demonstrated a good capability for 
identification of most of the species [26]. A recent study from Spain demonstrated that 
MALDI-TOF MS was able to correctly identify both reference strains and clinical 
isolates belonging to A. junii, A. haemolyticus, A. lwoffii, A. radioresistens, A. 
calcoaceticus, A. baumannii, and A. pittii [175]. Only isolates belonging to A. 
nosocomialis were incorrectly identified by MALDI-TOF MS due to the lack of an A. 
nosocomialis reference strain in the database provided by the system “Bruker database”. 
Nonetheless, the analysis identified unique MALDI-TOF MS patterns for every given 
species, including A. nosocomialis, allowing rapid and direct assertion of isolates into 
these species [175]. 
 
Our study showed that MALDI-TOF MS was suitable for precise species identification of 
isolates belonging to A. baumannii and A. pittii (the most prevalent Acinetobacter species 
in clinical isolates) as well as isolates belonging to A. lwoffii, A. ursingii, A. 
radioresistens, and A. calcoaceticus (Acinetobacter species encountered less frequently 
in clinical isolates) (Paper IV). MALDI-TOF MS incorrectly identified isolates belonging 
to A. soli and Acinetobacter gen. sp. “close to towneri” as A. baylyi and A. towneri, 
respectively. However, the closeness of these species demonstrated by MALDI-TOF MS 
was consistent with the outcomes of rpoB and 16S rDNA sequence analyses, confirming 
the high capability of MALDI-TOF MS (Paper I). Similar to the previously mentioned 
study from Spain, the main drawback of MALDI-TOF MS was the incorrect 
identification of isolates belonging to A. nosocomialis since it has so far been not 




Table 11. List of the Acinetobacter spp. reference strains included in BioTyper database 
Acinetobacter baumannii 13101_1 CHB Acinetobacter pittii Serovar 7 DSM 9308 DSM 
Acinetobacter baumannii B389 UFL Acinetobacter pittii Serovar 8 DSM 9309 DSM 
Acinetobacter baumannii DSM 30007T HAM Acinetobacter gerneri DSM 14967T HAM 
Acinetobacter baumannii DSM 30008 DSM Acinetobacter haemolyticus DSM 6962T DSM 
Acinetobacter baumannii DSM 30011 DSM Acinetobacter haemolyticus LMG 1033 HAM 
Acinetobacter baumannii LMG 994 HAM Acinetobacter johnsonii 10036669_102 USH 
Acinetobacter baylyi DSM 14959 DSM Acinetobacter johnsonii 2_1 TUB 
Acinetobacter baylyi DSM 14961T DSM Acinetobacter johnsonii DSM 6963T DSM 
Acinetobacter baylyi DSM 14963 DSM Acinetobacter johnsonii DSM 6963T HAM 
Acinetobacter bouvetii DSM 14964T DSM Acinetobacter junii DSM 14968 HAM 
Acinetobacter calcoaceticus B388 UFL Acinetobacter junii DSM 1532 DSM 
Acinetobacter calcoaceticus CCM 4503 CCM Acinetobacter junii DSM 6964T HAM 
Acinetobacter calcoaceticus CCM 4665 CCM Acinetobacter lwoffii 2_Ring240 MHH 
Acinetobacter calcoaceticus DSM 1139 DSM Acinetobacter lwoffii B101 UFL 
Acinetobacter calcoaceticus DSM 30006T HAM Acinetobacter lwoffii B138  UFL 
Acinetobacter guillouiae DSM 590 DSM Acinetobacter lwoffii DSM 2403T DSM 
Acinetobacter pittii Serovar 1 DSM 9337 DSM Acinetobacter lwoffii LB_101249_09 ERL 
Acinetobacter pittii Serovar 13 DSM 9312 DSM Acinetobacter parvus DSM 16617T HAM 
Acinetobacter pittii Serovar 14 DSM 9313 DSM Acinetobacter radioresistens B381 UFL 
Acinetobacter pittii Serovar 15 DSM 9314 DSM Acinetobacter radioresistens DSM 6976T HAM 
Acinetobacter pittii Serovar 18 DSM 9341 DSM Acinetobacter radioresistens LMG 10614 HAM 
Acinetobacter pittii Serovar 2 DSM 9306 DSM Acinetobacter schindleri DSM 16038T DSM 
Acinetobacter pittii Serovar 20 DSM 9317 DSM Acinetobacter sp. DSM 11042 DSM 
Acinetobacter pittii Serovar 21 DSM 9342 DSM Acinetobacter sp. DSM 11652 DSM 
Acinetobacter pittii Serovar 22 DSM 9318 DSM Acinetobacter sp. DSM 30009 DSM 
Acinetobacter pittii Serovar 23 DSM 9319 DSM Acinetobacter sp. DSM 46612 DSM 
Acinetobacter pittii Serovar 24 DSM 9320 DSM Acinetobacter tandoii DSM 14970T HAM 
Acinetobacter pittii Serovar 25 DSM 9343 DSM Acinetobacter tjernbergiae DSM 14966 DSM 
Acinetobacter pittii Serovar 26 DSM 9321 DSM Acinetobacter tjernbergiae DSM 14971T HAM 
Acinetobacter pittii Serovar 3 DSM 9307 DSM Acinetobacter towneri DSM 14962T HAM 
Acinetobacter pittii Serovar 4 DSM 9338 DSM Acinetobacter towneri DSM 14969 DSM 
Acinetobacter pittii Serovar 6 DSM 9340 DSM Acinetobacter ursingii DSM 16037T HAM 
 
Our study aimed to compare the performance of MALDI-TOF MS with two colorimetric 
semi-automated systems (VITEK 2 and Phoenix) for precise Acinetobacter species 
identification in routine clinical laboratories. Accordingly, the comparisions were 
performed based only on the concluding identification outcome provided by the system 
(for instance, no comparision was performed among MALDI-TOF MS patterns of 
different species). Overall, the study confirmed that MALDI-TOF MS represented a 
promising system for fast, simple, and reliable identification of members from the genus 
Acinetobacter. However, the system failed to correctly identify isolates of A. 
nosocomialis due to lack in the current database. Consequently, frequent updating of the 
supplementary databases is probably a major factor in improving the performance of the 
MALDI-TOF MS system. 
68 
 
6. Concluding remarks 
 
 
Acinetobacter baumannii is an important opportunistic pathogen that has a considerable 
capacity to acquire mechanisms conferring resistance to a wide range of antimicrobial 
drugs.  
 
The high proportion of A. nosocomialis, A. pittii in blood culture isolates from Norway 
points to the significant contribution of these species in the clinical setting and 
demonstrates the importance of molecular identification for precise Acinetobacter species 
identification. 
 
The predominance of the highly-successful CC92B/CC2P/international clone II in the 
current global A. baumannii population has now been established. However, several other 
long-standing or recently-emerging A. baumannii clones have certainly played a major 
supplementary role in the worldwide spread of MDR A. baumannii. 
 
The emergence of epidemic MDR A. baumannii clones in Norway and Sweden indicates 
the necessity of a screening programme for patients after hospitalization abroad, and 
strict infection control regimes to prevent further dissemination. 
 
The protein-fingerprinting-based MALDI-TOF MS system offers a promising tool for the 
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Table S1. Geographically and genotypically divergent 277 isolates selected for analyzing the global 
epidemiology of A. baumannii  
No. Isolate Country and year of 
isolationa 
Commentb Sequence typec Referenced 
1 62791 Spain/1993 Outbreak-related 1B (1-1-1-1-1-1-6) Pubmlst, [133] 
2 A92 Spain Carbapenem-S, blaOXA-69 2
B (2-2-2-1-1-2-7) [131, 132] 
3 228620 Spain/2000 Outbreak-related 3B (1-1-1-1-2-1-4) Pubmlst, [133] 
4 GEAC01/07 Italy/2007 MDR 4B (1-12-3-2-2-7-3) Pubmlst 
5 A230 UK Carbapenem-S, int. clone II, 
blaOXA-66 
4B (1-12-3-2-2-7-3) [131, 132] 
6 A397 Greece Carbapenem-I, int. clone II, 
blaOXA-66 
4B (1-12-3-2-2-7-3) [131, 132] 
7 60127 Spain/1997 Outbreak-related 5B (1-3-3-2-2-3-1) Pubmlst, [133] 
8 118151 Spain/1997 Outbreak-related 6B (1-4-3-2-2-3-3) Pubmlst, [133] 
9e RUH 134 The Netherlands/1982 Ref. strain, outbreak-related, int. 
clone II, blaOXA-66 
6B (1-4-3-2-2-3-3)                
98B (1-12-3-2-2-3-3) 
Pubmlst, [131-133] 
10 61588 Spain/2000 Outbreak-related 7B (3-3-3-2-3-3-8) Pubmlst, [133] 
11 61812 Spain/2000 Outbreak-related 8B (4-4-4-4-4-5-9) Pubmlst, [133] 
12 62309 Spain/2000 Outbreak-related 9B (1-3-3-2-2-6-8) Pubmlst, [133] 
13 2002-34100 Spain/2002 Outbreak-related 10B (1-4-3-2-2-7-3) Pubmlst, [133] 
14 DSM 30008 . Ref. strain 13B (1-7-8-9-1-4-14) Pubmlst, [133] 
15 W 5420 Germany/1991 Outbreak-related 15B (1-12-11-10-1-9-4) Pubmlst, [133] 
16 U 10247 Germany/1991 Outbreak-related 16B (10-12-4-11-11-9-5) Pubmlst, [133] 
17 St 14733 Germany/1990 Outbreak-related 17B (1-12-12-11-4-10-3) Pubmlst, [133] 
18 LS091 China/2005 - 17B (1-12-12-11-4-10-3) Pubmlst, [144] 
19 B0706-077 Korea/2006-07 Carbapenem-S, colistin-S 17B (1-12-12-11-4-10-3) [61] 
20 St 20820 Germany/1991 Outbreak-related 18B (10-13-4-11-12-11-5) Pubmlst, [133] 
21 St 15598 Germany/1991 Outbreak-related 19B (1-14-3-2-2-9-3) Pubmlst, [133] 
22 CGN-77 UK Outbreak-related 19B (1-14-3-2-2-9-3) Pubmlst, [143] 
23 St 17093 Germany/1991 Outbreak-related 20B (1-15-13-12-4-12-2) Pubmlst, [133] 
24 HZ104 China/2005 MDR, blaOXA-23-like carbapenem-
R, armA 
20B (1-15-13-12-4-12-2) Pubmlst, [144] 
25f M08-20 Malaysia/2008-09 Imipenem-R 20B (1-15-13-12-4-12-2) [146] 
26 A483 Morocco blaOXA-51 20
B (1-15-13-12-4-12-2) [131, 132] 
27 A187 South Africa Carbapenem-S, blaOXA-68 20
B (1-15-13-12-4-12-2) [131, 132] 
28 YMM14 Korea/2008 Carbapenem-S 20B (1-15-13-12-4-12-2) [60] 
29 St 1650 Germany/1992 Outbreak-related 21B (1-12-15-2-2-9-3) Pubmlst, [133] 
30 CGN-06 Germany/1991 Outbreak-related 22B (1-15-13-12-4-12-37) Pubmlst, [143] 
31 CGN-81 Germany/1996 Outbreak-related 23B (1-1-1-1-1-28-10) Pubmlst, [143] 
32 CGN-18 Denmark/1990 Sporadic 24B (1-1-22-1-4-20-16) Pubmlst, [143] 
33 CGN-48 Germany/1991 Sporadic 25B (1-1-41-6-23-31-26) Pubmlst, [143] 
34 CGN-09 Germany/1991 Outbreak-related 27B (1-12-15-2-2-3-3) Pubmlst, [143] 
35 CGN-55 Germany/1996 Outbreak-related 28B (1-12-3-2-2-35-4) Pubmlst, [143] 
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36 CGN-52 Denmark Sporadic 29B (1-12-3-28-2-29-4) Pubmlst, [143] 
37 CGN-56 Germany/1996 Outbreak-related 30B (1-12-3-29-2-34-4) Pubmlst, [143] 
38 CGN-39 Germany/1998 Outbreak-related 31B (1-12-39-25-21-3-25) Pubmlst, [143] 
39 CGN-44 Germany/1991 Sporadic 32B (1-12-4-11-4-28-2) Pubmlst, [143] 
40 CGN-46 Germany/1991 Sporadic 33B (1-12-4-11-4-29-2) Pubmlst, [143] 
41 CGN-23 Germany/1991 Sporadic 34B (1-15-13-12-4-49-37) Pubmlst, [143] 
42 CGN-71 USA/1995 Outbreak-related 35B (1-15-2-28-1-41-32) Pubmlst, [143] 
43 CGN-74 USA/1995 Outbreak-related 36B (1-15-2-28-1-44-32) Pubmlst, [143] 
44 CGN-15 Germany/1991 Sporadic 37B (1-19-21-17-1-18-14) Pubmlst, [143] 
45 CGN-19 Denmark/1990 Sporadic 38B (1-25-23-6-4-21-17) Pubmlst, [143] 
46 CGN-20 Germany/1991 Sporadic 39B (1-26-24-1-4-3-10) Pubmlst, [143] 
47 CGN-53 Denmark/1990 Sporadic 40B (1-3-6-1-4-34-10) Pubmlst, [143] 
48 CGN-30 Germany/1991 Sporadic 41B (1-31-31-24-4-10-21) Pubmlst, [143] 
49 CGN-54 Germany/1996 Sporadic 42B (1-34-14-28-22-35-2) Pubmlst, [143] 
50 CGN-82 Belgium Outbreak-related 43B (1-42-49-10-1-48-23) Pubmlst, [143] 
51 CGN-68 USA/1995 Sporadic 44B (10-12-1-33-4-29-31) Pubmlst, [143] 
52 CGN-29 Denmark/1990 Sporadic 45B (10-12-30-24-4-9-20) Pubmlst, [143] 
53 CGN-79 Germany/1996 Outbreak-related 46B (10-12-4-11-4-29-2) Pubmlst, [143] 
54 CGN-76 Germany Outbreak-related 47B (10-12-4-11-4-29-35) Pubmlst, [143] 
55 CGN-51 Denmark Sporadic 48B (10-12-4-6-4-33-2) Pubmlst, [143] 
56 CGN-10 Germany/1991 Sporadic 49B (10-19-17-16-4-9-2) Pubmlst, [143] 
57 CGN-43 Germany/1991 Sporadic 50B (10-34-40-26-22-27-2) Pubmlst, [143] 
58 CGN-45 Germany/1991 Sporadic 51B (11-12-4-11-1-28-2) Pubmlst, [143] 
59 CGN-01 Denmark Outbreak-related 52B (12-17-16-1-14-14-7) Pubmlst, [143] 
60 CGN-13 Germany/1991 Sporadic 53B (13-12-19-6-1-9-2) Pubmlst, [143] 
61 CGN-31 Germany/1998 Sporadic 54B (13-12-32-24-4-9-22) Pubmlst, [143] 
62 CGN-36 Germany/1991 Sporadic 55B (13-33-37-24-4-11-2) Pubmlst, [143] 
63 CGN-14 Germany/1991 Sporadic  56B (14-23-20-1-16-17-13) Pubmlst, [143] 
64 CGN-16 Germany/1991 Sporadic 57B (15-24-4-18-17-19-15) Pubmlst, [143] 
65 CGN-26 Germany/1991 Sporadic 58B (18-17-28-22-4-4-18) Pubmlst, [143] 
66 CGN-28 Germany/1991 Sporadic 59B (19-30-29-23-18-24-19) Pubmlst, [143] 
67 CGN-65 USA/1996 Outbreak-related 60B (2-21-12-32-26-39-2) Pubmlst, [143] 
68 CGN-33 Germany/1996 Outbreak-related 61B (20-12-34-24-1-9-2) Pubmlst, [143] 
69 CGN-34 Germany Sporadic 62B (21-31-35-24–1-25-23) Pubmlst, [143] 
70 CGN-47 Germany/1991 Sporadic 63B (23-35-3-27-23-30-19) Pubmlst, [143] 
71 CGN-49 Germany/1991 Sporadic 64B (24-1-42-13-24-32-26) Pubmlst, [143] 
72 CGN-69 USA/1996 Sporadic 65B (28-38-45-1-16-40-5) Pubmlst, [143] 
73 CGN-64 USA/1995 Outbreak-related 66B (28-38-45-31-16-30-5) Pubmlst, [143] 
74 CGN-75 USA/1995 Outbreak-related 67B (29-41-48-11-1-45-10) Pubmlst, [143] 
75 CGN-12 Germany/1991 Sporadic 68B (3-22-18-1-1-16-12) Pubmlst, [143] 
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76 C046 Korea/2003 Outbreak strain, carbapenem-R, 
ciprofloxacin-R, colistin-S 
69B (1-46-3-2-2-58-3) Pubmlst, [72] 
77 Q45 Australia/1998 Meropenem-S, amikacin-R, 
ciprofloxacin-R 
69B (1-46-3-2-2-58-3) Pubmlst 
78 C083 Korea/2005 Carbapenem-R 70B (1-46-3-2-1-58-3) Pubmlst, [72] 
79 C077 Korea/2005 Carbapenem-R 71B (1-46-3-2-2-58-4) Pubmlst, [72] 
80 C101 Korea/2006 Carbapenem-R 72B (1-15-2-28-1-55-4) Pubmlst, [72] 
81 D015 Korea/2006 Carbapenem-R 73B (1-47-53-1-1-59-32) Pubmlst, [72] 
82 Q18 Australia/2006 blaOXA-23 meropenem-R, 
amikacin-S, ciprofloxacin-S 
73B (1-47-53-1-1-59-32) Pubmlst, [145] 
83 04-888 Japan/2004 - 74B (1-3-3-2-2-75-3) Pubmlst 
84 09-946 Japan - 75B (1-3-3-2-2-11-3) Pubmlst 
85 F10 China/2005 MDR, blaOXA-23 carbapenem-R, 
armA 
75B (1-3-3-2-2-11-3) Pubmlst, [144] 
86 K08-22 Korea/2008-09 blaOXA-24-like Imipenem-R 75
B (1-3-3-2-2-11-3) [146] 
87 04-93 Japan/2002 - 76B (1-12-3-2-2-10-3) Pubmlst 
88 HK01-011 China/2008-09 blaOXA-58 imipenem-R 76
B (1-12-3-2-2-10-3) [146] 
89 09-780 Japan/2008 - 77B (1-1-66-12-33-76-21) Pubmlst 
90 09-775 Japan/2005 - 78B (13-26-67-40-1-22-7) Pubmlst 
91 09-782 Japan/2009 - 79B (34-12-68-41-32-7-46-79) Pubmlst 
92 09-785 Japan/2009 - 80B (34-12-68-41-34-10-4) Pubmlst 
93 04-565 Japan/2004 - 81B (1-54-69-11-4-69-45) Pubmlst 
94 07-791 Japan/2003 - 82B (1-12-70-15-4-52-45) Pubmlst 
95 09-781 Japan/2009 - 83B (21-12-2-15-35-77-4) Pubmlst 
96 08-943 Japan/2008 - 84B (1-12-2-15-22-72-5) Pubmlst 
97 08-1648 Japan/2008 - 85B (21-15-2-15-1-52-4) Pubmlst 
98 09-94 Japan/2008 - 86B (21-15-2-15-1-78-4) Pubmlst 
99 04-774 Japan/2004 - 87B (1-52-29-15-18-24-7) Pubmlst 
100 Ab08-13 Thailand/2008 - 88B (1-3-3-2-2-10-3) Pubmlst 
101 ZS4 China/2005 - 88B (1-3-3-2-2-10-3) Pubmlst, [144]
102 ZP5 China/2005 MDR, blaOXA-23 carbapenem-R, 
armA 
90B (1-3-3-2-2-62-3) Pubmlst, [144]
103 ZF5 China/2005 MDR, blaOXA-23 carbapenem-R, 
armA 
91B (22-15-13-12-4-62-2) Pubmlst, [144]
104 ZY136 China/2005 MDR, blaOXA-23 carbapenem-R, 
armA 
92B (1-3-3-2-2-7-3) Pubmlst, [144]
105 B0707-093 Korea/2006-07 blaOXA-23-like carbapenem-R, 
colistin-R 
92B (1-3-3-2-2-7-3) [61] 
106 GEAO11/07 Italy/2007 - 92B (1-3-3-2-2-7-3) Pubmlst 
107 Q17 Australia/2006 blaOXA-23-like meropenem-R, 
amikacin-R, ciprofloxacin-R 
92B (1-3-3-2-2-7-3) Pubmlst, [145] 
108 I05-06 India/2008-09 blaOXA-58 imipenem-R 92
B (1-3-3-2-2-7-3) [146] 
109 HAP32 Malaysia/2008-09 blaOXA-24 imipenem-R 92
B (1-3-3-2-2-7-3) [146] 
110 P08-009 Philippines/2008-09 blaOXA-24 imipenem-R 92
B (1-3-3-2-2-7-3) [146] 
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111 A401 Taiwan Carbapenem-R, int. clone II,  
blaOXA-82 
92B (1-3-3-2-2-7-3) [131, 132]
112 A484 UK Carbapenem-R, int. clone II, 
blaOXA-83 
92B (1-3-3-2-2-7-3) [131, 132]
113 A371 Czech Republic Carbapenem-R, int. clone II, 
blaOXA-83 
92B (1-3-3-2-2-7-3) [131, 132]
114 04-1278 Japan/2004 - 92B (1-3-3-2-2-7-3) Pubmlst 
115 GEBB14/07 Italy/2007 - 93B (1-12-13-6-11-1-4) Pubmlst 
116 GEBC16/07 Italy/2007 MDR 94B (2-12-12-1-1-4-4) Pubmlst 
117 GEAW22/07 Italy/2007 MDR 95B (10-12-4-11-1-9-5) Pubmlst 
118 CQ95 China/2005 - 95B (10-12-4-11-1-9-5) Pubmlst 
119 A384 Norway Carbapenem-I, int. clone I, 
blaOXA-69  
95B (10-12-4-11-1-9-5) [131, 132]
120 1A2 China/2005 Outbreak-related, MDR, blaOXA-
23-like carbapenem-R, colistin-S 
96B (1-43-50-31-1-50-26) Pubmlst, [142] 
121 4017355 Spain/2008 - 97B (1-17-8-10-28-51-38) Pubmlst 
122 A24 UK Carbapenem-S, int. clone II, 
blaOXA-66 
98B (1-12-3-2-2-3-3) [131, 132]
123 A392 Germany Carbapenem-R, int. clone II, 
blaOXA-66 
98B (1-12-3-2-2-3-3) [131, 132]
124 Ab21 Argentine/2000 - 99B (1-15-52-10-28-3-32) Pubmlst 
125 82 Argentina/2002 Environmental (bed-rail) 100B (1-15-52-10-28-55-32) Pubmlst 
126 Ab31 Argentine/2000 - 101B (1-15-12-6-28-12-40) Pubmlst 
127 Ab149 Argentine/1990 - 102B (1-15-52-10-28-12-32) Pubmlst 
128 Ab545 Argentine/1991 - 103B (12-17-12-1-29-3-39) Pubmlst 
129 Ab244 Argentine/1997 - 104B (12-17-12-1-29-57-39) Pubmlst 
130 Ab295 Argentine/1998 - 105B (31-45-51-6-30-53-6) Pubmlst 
131 R6 China/2007 - 106B (1-3-15-2-2-7-3) Pubmlst 
132 CYH13 Korea/2008 Carbapenem-S 106B (1-3-15-2-2-7-3) [60] 
133 Ab170 Argentine/1990 - 107B (1-17-12-1-29-57-39) Pubmlst 
134 Ab834 Argentine/2005 - 108B (10-12-4-6-4-9-5) Pubmlst 
135f I02-18 India/2008-09 Imipenem-R 108B (10-12-4-6-4-9-5) [146] 
136 A63 Argentine Carbapenem-S, int. clone I, 
blaOXA-69 
109B (10-12-4-11-4-9-5) [131, 132]
137 04-1279 Japan/2004 - 109B (10-12-4-11-4-9-5) Pubmlst 
138 A442 Bulgaria Carbapenem-S, int. clone I, 
blaOXA-69 
109B (10-12-4-11-4-9-5) [131, 132]
139 A368 UK Carbapenem-S, int. clone I, 
blaOXA-112 
109B (10-12-4-11-4-9-5) [131, 132]
140 U557 Korea/2006-07 carbapenem-R, colistin-R 110B (1-15-2-28-1-52-32) [61] 
141 Ab253 Argentine/1997 - 110B (1-15-2-28-1-52-32) Pubmlst 
142 22 Argentina/2002 Environmental (bed-rail) 113B (1-15-52-10-28-56-32) Pubmlst 
143 Ab592 Argentine/1995 - 114B (1-15-52-10-28-57-32) Pubmlst 
144 GEBF02/08 Italy/2008 MDR 115B (2-1-12-1-1-4-5) Pubmlst 
145 GEBG03/08 Italy/2008 - 116B (1-15-4-11-4-4-2) Pubmlst 
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146 GEBL06/08 Italy/2008 - 117B (1-15-2-2-1-4-5) Pubmlst 
147 GEBM07/08 Italy/2008 MDR 118B (1-3-3-2-2-3-3) Pubmlst 
148 TW01-010 Taiwan/2008-09 blaOXA-24-like imipenem-R 118
B (1-3-3-2-2-3-3) [146] 
149 A343 UK Carbapenem-S, int. clone II, 
blaOXA-109 
118B (1-3-3-2-2-3-3) [131, 132]
150 Ab03-168 Thailand/2003 - 119B (1-15-12-6-28-59-40) Pubmlst 
151 24029815 Spain/2006 - 121B (1-17-52-10-28-63-32) Pubmlst 
152 ACAT195 USA/2008 - 122B (1-3-61-2-2-7-3) Pubmlst 
153 ACAT199 USA/2008 - 123B (1-35-61-2-2-3-3) Pubmlst 
154 ACAT1204 USA/2005 - 124B (1-17-60-10-28-66-32) Pubmlst 
155 Q47 Australia/1999 blaOXA-23 meropenem-R, 
amikacin-R, ciprofloxacin-R 
125B (1-52-59-12-1-18-44) Pubmlst, [145] 
156 Q55 Australia/2003 Meropenem-S, amikacin-R, 
ciprofloxacin-R 
126B (10-53-4-11-4-64-5) Pubmlst, [145] 
157 Q22 Australia/2007 blaOXA-23  meropenem-R, 
amikacin-S, ciprofloxacin-S 
127B (1-33-57-11-26-11-6) Pubmlst, [145] 
158 Q29 Australia/2008 Meropenem-S, amikacin-S, 
ciprofloxacin-S 
128B (2-44-58-1-1-54-41) Pubmlst, [145] 
159 Q44 Australia/2009 Meropenem-S, amikacin-S, 
ciprofloxacin-S 
129B (1-38-42-37-4-11-43) Pubmlst, [145] 
160 Q56 Australia/2009 - 130B (1-12-3-2-2-65-3) Pubmlst, [145] 
161 256 Argentina/2002 Environmental (dispenser) 131B (1-15-60-10-28-56-32) Pubmlst 
162 Ab3135 Brazil/2007 blaOXA-23 carbapenem-R, SG10, 
blaOXA-95 
132B (1-12-71-2-1-79-30) Pubmlst, [130] 
163 Ab3356 Brazil/2007 blaOXA-23 carbapenem-R, SG11, 
blaOXA-69 
134B (2-12-73-12-1-9-47) Pubmlst, [130] 
164 09-1484 Japan/2009 - 135B (10-53-74-11-4-80-5) Pubmlst 
165 H401 China/2009 - 136B (1-3-3-2-2-16-3) Pubmlst 
166 LAMAB027 China/2009 MDR 137B (1-3-3-2-2-12-3) Pubmlst 
167 LAMAB020 China/2009 MDR 138B (1-3-3-2-2-50-3) Pubmlst 
168 K102-07 Korea/2008-09 blaOXA-24-like imipenem-R 138
B (1-3-3-2-2-50-3) [146] 
169 KNSS0821 
(KSS21) 
Korea/2008 Carbapenem-S 139B (1-15-12-6-28-59-3) Pubmlst, [60] 
170 GYMC0812 
(GY12) 
Korea/2008 Carbapenem-S 140B (1-15-12-6-28-59-32) Pubmlst, [60] 
171 IJMC0822 
(IJ22) 
Korea/2008 Carbapenem-S 141B (1-47-3-2-2-7-30) Pubmlst, [60] 
172 IJMC0834 Korea/2008 - 142B (10-12-4-11-1-9-30) Pubmlst 
173 CHA0839 
(CHA39) 
Korea/2008 Carbapenem-S 143B (1-47-67-28-1-10-6) Pubmlst, [60] 
174 KNSM0820 Korea/2008 - 144B (21-35-2-28-22-52-4) Pubmlst 
175 IJMC0835 Korea/2008 - 145B (21-35-2-28-1-52-4) Pubmlst 
176 CNMC0810 
(CN10) 
Korea/2008 Carbapenem-S 146B (1-15-13-12-4-14-2) Pubmlst, [60] 
177g Not found China/2005 Carbapenem-S 146B (1-15-13-12-4-14-2) [144] 
178 IJMC0801 Korea/2008 - 147B (1-54-62-31-4-55-45) Pubmlst 
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Korea/2008 Carbapenem-S 153B (21-35-2-28-1-84-4) Pubmlst, [60] 
185 KSMC0830 
(KS30) 
Korea/2008 Carbapenem-S 154B (21-55-13-28-1-84-2) Pubmlst, [60] 
186 KMMC0807 
(KMC7) 
Korea/2008 Carbapenem-S 155B (1-57-78-12-1-25-51) Pubmlst, [60] 
187 CHA0815 
(CHA15) 
Korea/2008 Carbapenem-S 156B (1-15-2-28-1-25-32) Pubmlst, [60] 
188 CHA0826 
(CHA26) 
Korea/2008 Carbapenem-S 157B (1-31-79-43-4-25-50) Pubmlst, [60] 
189 CHA0833 
(CHA33) 
Korea/2008 Carbapenem-S 158B (21-35-2-28-1-85-4) Pubmlst, [60] 
190 CHA0851 
(CHA51) 
Korea/2008 Carbapenem-S 159B (1-57-78-12-1-10-51) Pubmlst, [60] 
191 YNMC0845 
(YN45) 
Korea/2008 Carbapenem-S 160B (1-56-2-44-1-52-6) Pubmlst, [60] 
192 IJMC0840 
(IJ40) 
Korea/2008 Carbapenem-S 161B (21-12-2-28-1-86-4) Pubmlst, [60] 
193 KMSS0815 
(KSS15) 
Korea/2008 Carbapenem-S 162B (40-1-83-6-4-7-13) Pubmlst, [60] 
194 KYMC0823 
(KY23) 
Korea/2008 Carbapenem-S 163B (33-12-40-26-32-91-5) Pubmlst, [60] 
195 CHA0818 
(CHA18) 
Korea/2008 Carbapenem-S 164B (33-12-40-26-32-84-5) Pubmlst, [60] 
196 CHA0827 
(CHA27) 
Korea/2008 Carbapenem-S 165B (33-12-40-26-25-84-5) Pubmlst, [60] 
197 CYMC0823 
(CYM23) 
Korea/2008 Carbapenem-S 166B (33-12-40-26-32-87-5) Pubmlst, [60] 
198 CSMC0830 
(CS30) 
Korea/2008 Carbapenem-S 167B (33-12-40-26-32-83-5) Pubmlst, [60] 
199 KNSM0811 
(KSM11) 
Korea/2008 Carbapenem-S 168B (1-12-65-45-4-88-26) Pubmlst, [60] 
200 MJMC0826 
(MJ26) 
Korea/2008 Carbapenem-S 169B (1-34-70-28-4-90-45) Pubmlst, [60] 
201 CHA0831 
(CHA31) 
Korea/2008 Carbapenem-S 170B (1-12-80-28-35-89-30) Pubmlst, [60] 
202 CHA0842 
(CHA42) 
Korea/2008 Carbapenem-S 171B (1-48-65-45-4-90-26) Pubmlst, [60] 
203 CCH0815 
(CCH15) 
Korea/2008 Carbapenem-S 172B (1-34-80-28-1-72-45) Pubmlst, [60] 
204 CHA0850 
(CHA50) 
Korea/2008 Carbapenem-S 173B (1-58-29-2-4-9-53) Pubmlst, [60] 
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205 CSMC0841 
(CS41) 
Korea/2008 Carbapenem-S 174B (11-27-14-21-15-22-15) Pubmlst, [60] 
206 YMC42 Korea/2008 Carbapenem-S 175B (1-17-82-39-1-92-7) [60] 
207 CYH28 Korea/2008 Carbapenem-S 176B (21-48-58-42-36-83-4) [60] 
208 KS49 Korea/2008 Carbapenem-S 177B (33-21-12-49-1-54-7) [60] 
209 YMM05 Korea/2008 Carbapenem-S 178B (31-61-70-46-16-58-6) [60] 
210 KSMC0847 
(KS47) 
Korea/2008 Carbapenem-S 179B (35-62-75-28-35-7-30) Pubmlst, [60] 
211 MJMC0812 
(MJ12) 
Korea/2008 Carbapenem-S 180B (1-63-12-6-28-59-30) Pubmlst, [60] 
212 CYH0826 
(CYH26) 
Korea/2008 Carbapenem-S 181B (1-64-76-1-23-81-32) Pubmlst, [60] 
213 KNSM0807 
(KSM07) 
Korea/2008 Carbapenem-S 182B (35-60-77-11-26-11-48) Pubmlst, [60] 
214 KNSS0810 Korea/2008 - 183B (1-17-81-1-1-91-26) Pubmlst 
215 KNSS0836 Korea/2008 - 184B (36-31-70-28-4-54-4) Pubmlst 
216 LAMAB033 China/2009 MDR 184B (36-31-70-28-4-54-4) Pubmlst 
217 KYMC0822 Korea/2008 - 185B (37-53-13-47-32-64-52) Pubmlst 
218 SCMC0819 Korea/2008 - 186B (38-59-80-48-18-58-43) Pubmlst 
219 A20 France Carbapenem-R, int. clone III, 
blaOXA-71 
187B (1-1-1-1-1-9-6) [131, 132]
220 A377 Germany Carbapenem-R, int. clone III, 
blaOXA-71 
187B (1-1-1-1-1-9-6) [131, 132]
221 A329 Spain Carbapenem-R, int. clone III, 
blaOXA-71 
187B (1-1-1-1-1-9-6) [131, 132]
222 A387 Greece Carbapenem-I, int. clone II, 
blaOXA-66 
189B (1-12-3-2-2-4-3) [131, 132]
223 Mon2 Italy/2007 - 196B (2-21-12-32-26-63-5) Pubmlst 
224 Mon1 Italy/2008 - 197B (10-12-4-11-4-64-5) Pubmlst 
225 Ab08-26 Thailand/2008 - 200B (17-29-24-12-19-31-40) Pubmlst 
226 Ab04-32 Thailand/2004 - 202B (32-46-4-11-4-32-5) Pubmlst 
227 NYD625 USA/2008 - 203B (41-1-72-32-1-98-6) Pubmlst 
228 NYD644 USA/2009 - 204B (1-17-61-2-2-99-3) Pubmlst 
229 BJH07 USA/2008 - 205B (1-17-60-10-28-99-32) Pubmlst 
230 UCLA 2 USA/2009 - 206B (1-17-72-2-2-99-3) Pubmlst 
231 UCLA 3 USA/2009 - 207B (10-53-84-11-4-100-5) Pubmlst 
232 UCLA 11 USA/2009 - 208B (1-3-61-2-2-97-3) Pubmlst 
233 207 Argentina/2002 Environmental (bed-rail) 209B (1-15-60-39-28-56-32) Pubmlst 
234 AB104 Argentina/1992 - 210B (1-47-52-10-28-4-32) Pubmlst 
235 AB170 Argentina/1989 - 211B (1-52-62-39-4-4-38) Pubmlst 
236 202 Argentina/2002 Environmental (personnel hand) 212B (1-15-60-10-28-56-9) Pubmlst 
237 72 Argentina/2002 Environmental (personnel hand) 213B (1-52-52-10-28-55-32) Pubmlst 
238 AB17 Argentina/2002 - 214B (1-15-60-10-28-57-32) Pubmlst 
239 279 Argentina/2002 - 215B (12-17-72-1-26-3-7) Pubmlst 
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240 49631 Argentina/2008 - 216B (10-12-32-11-12-9-5) Pubmlst 
241 287 Argentina/2006 - 217B (10-12-4-5-12-57-5) Pubmlst 
242 OXA-23 
clone 1 
. - 218B (1-3-61-2-2-102-3) Pubmlst 
243 TUM10634 Japan/2007 - 219B (1-3-61-2-2-101-3) Pubmlst 
244 H07-988 Korea/2007 - 220B (1-3-3-2-1-7-3) Pubmlst 
245 TUM10639 Japan/2007 - 221B (33-57-86-10-1-103-6) Pubmlst 
246 TUM10641 Japan/2007 - 222B (1-15-87-28-1-104-32) Pubmlst 
247 LAMAB032 China/2009 MDR 223B (1-17-3-2-2-56-3) Pubmlst 
248 405 E4 China/2006 - 224B (1-34-72-6-1-18-45) Pubmlst 
249 C186 Brazil/2007 - 225B (12-17-72-1-29-99-39) Pubmlst 
250 I128 Brazil/2008 - 226B (12-17-72-1-29-16-54) Pubmlst 
251 I056 Brazil/2007 - 227B (1-15-60-10-28-99-32) Pubmlst 
252 I013 Brazil/2007 - 228B (1-15-87-28-1-16-32) Pubmlst 
253 C012 Brazil - 229B (1-15-87-28-1-107-32) Pubmlst 
254 C581 Brazil - 230B (1-17-60-10-28-108-32) Pubmlst 
255 I006 Brazil/2007 - 231B (10-12-88-11-4-98-5) Pubmlst 
256 252 Brazil - 232B (21-48-89-50-36-109-4) Pubmlst 
257 282 Brazil - 233B (1-15-60-10-28-106-32) Pubmlst 
258 596 Brazil - 234B (21-48-89-42-36-109-4) Pubmlst 
259 440 Brazil - 235B (1-69-90-2-1-79-30) Pubmlst 
260 487 Brazil - 236B (12-17-72-1-29-102-39) Pubmlst 
261 597 Brazil - 237B (1-15-60-10-28-106-4) Pubmlst 
262 546 Brazil - 238B (1-3-61-2-38-97-3) Pubmlst 
263 A47 Germany Carbapenem-S, int. clone II, 
blaOXA-66 
239B (1-12-3-2-2-55-3) Pubmlst, [131, 132] 
264 A37 Singapore Carbapenem-S, blaOXA-64 240
B (1-15-2-15-1-52-16) Pubmlst, [131, 132] 
265 A60 Argentina Carbapenem-S, int. clone II, 
blaOXA-65 
241B (1-15-52-10-28-12-16) Pubmlst, [131, 132] 
266 A135 Belgium Carbapenem-S, blaOXA-111 242
B (1-28-49-10-1-24-4) Pubmlst, [131, 132] 
267 A457 Estonia Carbapenem-S, blaOXA-106 243
B (1-50-13-6-4-60-42) Pubmlst, [131, 132] 
268 A13 The Netherlands Carbapenem-S, int. clone III, 
blaOXA-71 
244B (1-51-1-1-1-9-6) Pubmlst, [131, 132] 
269 A404 Poland Carbapenem-I, int. clone I, 
blaOXA-110 
245B (10-12-4-11-4-4-5) Pubmlst, [131, 132] 
270 A443 Slovenia Carbapenem-I, int. clone I, 
blaOXA-107 
245B (10-12-4-11-4-4-5) Pubmlst, [131, 132] 
271 A424 Croatia Carbapenem-R, int. clone I, 
blaOXA-107 
246B (10-12-4-11-4-55-5) Pubmlst, [131, 132] 
272 A479 UK (exported from 
Pakistan) 
Carbapenem-I, int. clone I, 
blaOXA-69 
247B (10-12-4-11-4-58-5) Pubmlst, [131, 132] 
273 A388 Greece Carbapenem-S, blaOXA-92 248
B (10-18-4-11-4-11-5) Pubmlst, [131, 132] 
274 A374 The Netherlands blaOXA-51 249
B (12-18-12-1-29-14-39) Pubmlst, [131, 132] 
275 A125 Northern Ireland blaOXA-51 250
B (12-18-12-1-29-55-23) Pubmlst, [131, 132] 
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276 A95 Italy Carbapenem-S, blaOXA-98 251
B (32-48-54-35-1-11-40) Pubmlst, [131, 132] 
277 A473 Poland Carbapenem-I, int. clone II, 
blaOXA-108 
252B (1-49-38-12-31-56-4) Pubmlst, [131, 132] 
aUK, the United Kingdom; USA, the United States of America. 
bRef., reference; Int., international; S, susceptible; I, intermediate; R, resistant; MDR, multidrug resistant; SG, sequence 
group. 
cSTB, sequence type according to Bartual’s scheme.  
dPubmlst, http://pubmlst.org/abaumannii/. 
eRUH 134 was assigned into two different STs by the reference articles. 
fM08-20 and I02-18 were blaOXA-23-like-, blaOXA-24-like-, and blaOXA-58-like-neg [146]. 
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1 LUH 3783 Czech Republic/1991 MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
2 LUH 6015 Italy/1998 MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
3 LUH 6224 Australia/1995 MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
4 LUH 7140 UK/2000 MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
5 LUH 8592 Bulgaria/2001 MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
6 LUH 9668 Ireland/2003 MDR, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
7 RUH 3247 Belgium/1990 MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
8 LUH 6050 South Africa MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
9 LUH 5881 Spain/1998 MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
10 LUH 6125 Poland/1998 MDR, outbreak-related, int. clone I 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
11 AYE France/2001 MDR, outbreak-related 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
12 AB0057 USA/2004 MDR 1P (1-1-1-1-5-1-1) Pasteur MLST, [39] 
13 3887 Greece/2006 blaOXA-58 and blaVIM-4 imipenem-R, 
outbreak-related, int. clone I 
1P (1-1-1-1-5-1-1) [82] 
14 A1755 UK/2000 Sporadic, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
15 LUH 4629 Czech Republic/1996 MDR, outbreak-related, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
16 LUH 5682 The Netherlands/1993 MDR, isolated from horse, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
17 LUH 6024 Spain/1998 MDR, outbreak-related, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
18 RUH 3422 Denmark/1984 Antibiotic-S, sporadic, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
19 LUH 5868 France/1997 MDR, outbreak-related, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
20 LUH 6021 Poland/1998 MDR, outbreak-related, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
21 LUH 8143 Singapore/1997 MDR, outbreak-related, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
22 RUH 3381 Ireland/1989 MDR, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
23 LUH 6231 Australia/1999 MDR, outbreak-related, int. clone II 2P (2-2-2-2-2-2-2) Pasteur MLST, [39] 
24 3979 Italy/2006 MDR, outbreak-related, blaOXA-58 
carbapenem-R, colistin-S, int. clone II 
2P (2-2-2-2-2-2-2) [127] 
25 3894 Greece/2006 blaOXA-58 and blaVIM-1 imipenem-R, 
outbreak strain, int. clone II 
2P (2-2-2-2-2-2-2) Pasteur MLST, [82] 
26 4026 Lebanon/2007 blaOXA-58 imipenem-R, outbreak strain, 
int. clone II 
2P (2-2-2-2-2-2-2) Pasteur MLST, [82] 
27 ANT229 Turkey/2009 - 2P (2-2-2-2-2-2-2) Pasteur MLST 
28 AO-12066 
(K51-54) 
Sweden/2004 MDR, blaOXA-58-like carbapenem-R, int. 
clone II 
2P (2-2-2-2-2-2-2) Pasteur MLST, paper 
III 
29 LUH 6009 France/1997 MDR, outbreak-related, int. clone III 3P (3-3-2-2-3-1-3) Pasteur MLST, [39] 
30 LUH 6012 Italy/1998 MDR, outbreak-related, int. clone III 3P (3-3-2-2-3-1-3) Pasteur MLST, [39] 
31 LUH 6028 Spain/1998 MDR, outbreak-related, int. clone III 3P (3-3-2-2-3-1-3) Pasteur MLST, [39] 
32 LUH 9536 Belgium/1993 MDR, outbreak-related, int. clone III 3P (3-3-2-2-3-1-3) Pasteur MLST, [39] 
33 4025 Lebanon/2005 blaOXA-58 imipenem-R, int. clone III 3
P (3-3-2-2-3-1-3) Pasteur MLST, [39] 
34 LUH 8225 The Netherlands/2002 Antibiotic-S, sporadic 4P (1-3-3-2-4-1-4) Pasteur MLST, [39] 





MDR, blaOXA-58-like carbapenem-R, 
SG7 
5P (4-1-2-2-4-1-5) Pasteur MLST, paper 
III  
37 A955 UK/2000 Sporadic 6P (5-4-4-1-3-3-4) Pasteur MLST, [39] 
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38 LUH 3782 Czech Republic/1991 MDR, int. clone I 7P (1-1-1-2-5-1-1) Pasteur MLST, [39] 
39 RUH 0510 The Netherlands/1984 MDR, outbreak-related, int. clone I 8P (1-1-1-1-1-1-1) Pasteur MLST, [39] 
40 700 Italy/1999 - 8P (1-1-1-1-1-1-1) Pasteur MLST 
41 3886 Greece/2005 - 8P (1-1-1-1-1-1-1) Pasteur MLST 
42 LUH 4633 Czech Republic/1993 Antibiotic-S 9P (3-1-5-3-6-1-3) Pasteur MLST, [39] 
43 LUH 4641 Czech Republic/1994 MDR 10P (1-3-2-1-4-4-4) Pasteur MLST, [39] 
44 LUH 6237 Australia/1981-91 Antibiotic-S, sporadic 10P (1-3-2-1-4-4-4) Pasteur MLST, [39] 
45 LUH 4718 Czech Republic/1994 Antibiotic-S 11P (1-2-6-2-3-4-4) Pasteur MLST, [39] 
46 LUH 4727 Czech Republic/1994 Antibiotic-S 12P (3-5-7-1-7-2-6) Pasteur MLST, [39] 
47 LUH 5687 The Netherlands/1996 Antibiotic-S, Isolated from dog, int. 
clone III 
13P (3-1-2-2-4-1-3) Pasteur MLST, [39] 
48 LUH 5874 France/1997 MDR, outbreak-related 14P (3-3-2-2-3-1-7) Pasteur MLST, [39] 
49 LUH 8406 Czech Republic/2001 MDR 15P (6-6-8-2-3-5-4) Pasteur MLST, [39] 
50 LUH 6374 The Netherlands/2000 MDR, outbreak-related 15P (6-6-8-2-3-5-4) Pasteur MLST, [39] 
51 LUH 8147 Argentina/1995 MDR, outbreak-related 15P (6-6-8-2-3-5-4) Pasteur MLST, [39] 
52 3868 Turkey/2003 blaOXA-58-like imipenem-R, outbreak-
related 
15P (6-6-8-2-3-5-4) Pasteur MLST, [82] 
53 Ab54 Spain/2003-04 Imipenem-R, outbreak-related 15P (6-6-8-2-3-5-4) [137] 
54 LUH 6639 The Netherlands/2001 MDR, outbreak-related 16P (7-7-2-2-8-4-4) Pasteur MLST, [39] 
55 SDF France/<1999 Antibiotic-S, sporadic 17P (3-29-30-1-9-1-4) Pasteur MLST, [39] 
56 LUH 8326 The Netherlands/2002 Antibiotic-S, sporadic 18P (1-8-9-2-4-6-4) Pasteur MLST, [39] 
57 LUH 8605 Bulgaria/2002 MDR, sporadic, int. clone I 19P (1-2-1-1-5-1-1) Pasteur MLST, [39] 
58 LUH 8723 The Netherlands/2003 MDR, outbreak-related, int. clone I 20P (3-1-1-1-5-1-1) Pasteur MLST, [39] 
59 2979 Italy/2002 Imipenem-S, outbreak-related, int. 
clone I 
20P (3-1-1-1-5-1-1) Pasteur MLST, [82] 
60 3130 Lebanon/2004 blaOXA-58 imipenem-R, outbreak-
related, int. clone I 
20P (3-1-1-1-5-1-1) Pasteur MLST, [82] 
61 LUH 9415 The Netherlands/2004 Antibiotic-S, sporadic 21P (3-3-2-2-4-4-8) Pasteur MLST, [39] 
62 RUH 1093 The Netherlands/1985 Antibiotic-S, sporadic 22P (3-9-3-2-4-1-9) Pasteur MLST, [39] 
63 RUH 1316 The Netherlands/1964 Antibiotic-S 23P (1-3-10-1-4-4-4) Pasteur MLST, [39] 
64 AO-11921 
(K51-60) 
Sweden/2006 MDR, blaOXA-58-like carbapenem-R, 
SG5 
23P (1-3-10-1-4-4-4) Pasteur MLST, paper 
III 
65 RUH 1317 The Netherlands/1985 Antibiotic-S 24P (1-10-2-2-9-1-10) Pasteur MLST, [39] 
66 RUH 1486 The Netherlands/1985 Antibiotic-S, sporadic  25P (3-3-2-4-7-2-4) Pasteur MLST, [39] 
67 3865 Turkey/2005 blaOXA-23 and blaOXA-58 imipenem-R, 
outbreak-related 
25P (3-3-2-4-7-2-4) Pasteur MLST, [82] 
68 3890 Greece/2003 blaOXA-58 imipenem-R; outbreak-related 25
P (3-3-2-4-7-2-4) Pasteur MLST, [82] 
69 4190 Italy/2009 blaOXA-72 imipenem-R, outbreak-
related 





MDR, blaOXA-23-like carbapenem-R, 
SG12 




Singapore/1996 blaOXA-23, blaOXA-64 25
P (3-3-2-4-7-2-4) Pasteur MLST 
72 RUH 1907 The Netherlands/1986 Antibiotic-S, sporadic 26P (1-2-11-5-3-1-11) Pasteur MLST, [39] 
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73 RUH 2180 The Netherlands/1987 Antibiotic-S, sporadic 27P (3-3-12-2-9-7-4) Pasteur MLST, [39] 
74 RUH 2208 Sweden/1980-81 Antibiotic-S, sporadic 28P (1-1-2-2-10-4-4) Pasteur MLST, [39] 
75 RUH 3413 UK/1981 MDR, sporadic 29P (1-3-13-1-5-8-12) Pasteur MLST, [39] 
76 RUH 3423 Denmark/1990 Antibiotic-S, sporadic 30P (1-1-2-5-3-2-3) Pasteur MLST, [39] 
77 RUH 3424 Denmark/1990 Antibiotic-S, sporadic 31P (1-2-2-2-11-1-1) Pasteur MLST, [39] 
78 RUH 3425 Denmark/1990 Antibiotic-S, sporadic 32P (1-1-2-2-3-4-4) Pasteur MLST, [39] 
79 Ab55 Spain/2004-07 Imipenem-R, outbreak-related 32P (1-1-2-2-3-4-4) [137] 
80 RUH 3429 Sweden/1980-81 Antibiotic-S, sporadic 34P (8-1-14-3-12-1-13) Pasteur MLST, [39]e 
81 LUH 4631 Czech Republic/1992 Antibiotic-S 35P (9-3-2-2-5-4-14) Pasteur MLST, [39]e 
82 LUH 4707 Czech Republic/1992 Antibiotic-S 36P (1-2-2-2-3-1-2) Pasteur MLST, [39]e 
83 LUH 4708 Czech Republic/1992 Antibiotic-S 37P (3-2-2-2-7-1-2) Pasteur MLST, [39]e 
84 LUH 4709 Czech Republic/1993 Antibiotic-S 38P (3-2-15-6-6-4-5) Pasteur MLST, [39]e 
85 LUH 4711 Czech Republic/1992 Antibiotic-S 39P (10-4-3-2-13-1-2) Pasteur MLST, [39]e 
86 LUH 4722 Czech Republic/1996 Antibiotic-S 40P (1-2-2-2-5-1-14) Pasteur MLST, [39]e 
87 LUH 4725 Czech Republic/1993 Antibiotic-S 41P (1-1-2-2-12-1-5) Pasteur MLST, [39]e 
88 LUH 5684 The Netherlands/1994 Antibiotic-S, isolated from horse 42P (3-11-16-1-13-1-15) Pasteur MLST, [39] 
89 LUH 5685 The Netherlands/1994 Antibiotic-S, isolated from dog 43P (3-3-13-2-4-4-5) Pasteur MLST, [39] 
90 LUH 5691 The Netherlands/1997 Antibiotic-S, isolated from cat 44P (11-2-2-4-13-1-2) Pasteur MLST, [39] 
91 LUH 6011 Greece/1997 MDR, outbreak-related, int. clone II 45P (2-6-2-2-2-2-2) Pasteur MLST, [39] 
92 LUH 7852 Czech Republic/1994 MDR 46P (5-12-11-2-14-9-14) Pasteur MLST, [39] 
93 LUH 7855 Czech Republic/2000 MDR, outbreak-related, int. clone II 47P (2-13-2-2-2-2-20) Pasteur MLST, [39] 
94 LUH 8088 The Netherlands/2002 Antibiotic-S, sporadic 48P (3-14-2-2-15-4-5) Pasteur MLST, [39] 
95 LUH 9084 The Netherlands/2003 Antibiotic-S, sporadic 49P (3-3-6-2-3-1-5) Pasteur MLST, [39] 
96 AB900 USA/2003 Antibiotic-S 49P (3-3-6-2-3-1-5) Pasteur MLST, [39] 
97 LUH 9136 The Netherlands/2004 MDR, sporadic 50P (3-15-17-2-3-1-2) Pasteur MLST, [39] 
98 RUH 0414 The Netherlands/1978 Antibiotic-S 51P (3-16-6-2-16-4-2) Pasteur MLST, [39] 
99 RUH 1752 The Netherlands/1986 Antibiotic-S, outbreak-related 52P (3-2-2-7-9-1-5) Pasteur MLST, [39] 
100 RUH 1063 <1948 Antibiotic-S 52P (3-2-2-7-9-1-5) Pasteur MLST, [39] 
101 ATCC 17904 <1962 Antibiotic-S 54P (12-3-18-2-17-4-5) Pasteur MLST, [39] 
102 RUH 2688 The Netherlands/1987 Antibiotic-S, sporadic 55P (13-4-2-2-6-1-16) Pasteur MLST, [39] 
103 RUH 3410 UK/1982 Antibiotic-S, sporadic 56P (3-17-7-2-18-1-2) Pasteur MLST, [39] 
104 RUH 3414 UK/1988 Antibiotic-S, sporadic 57P (1-3-17-5-3-1-14) Pasteur MLST, [39] 
105 SB 1414 The Netherlands/1997 Antibiotic-S 58P (13-4-2-2-7-1-2) Pasteur MLST, [39] 
106 LUH 6049 Turkey/1997 MDR, int. clone II 59P (3-2-19-2-5-2-5) Pasteur MLST, [39] 
107 3978 Italy/2006 MDR, outbreak-related, blaOXA-58 
carbapenem-R, colistin-S, SG8, 
blaOXA-90 
78P (25-3-6-2-28-1-29) [127] 
108 Ab1 Spain/2006-07 Imipenem-R, outbreak-related 79P (26-2-2-2-29-4-5) [137] 
109 Ab9 Spain/2005-07 Imipenem-R, outbreak-related 80P (1-1-10-1-4-4-5) [137] 
110 Ab20 Spain/1999-2000 Imipenem-R, outbreak-related 81P (1-1-1-1-5-1-2) [137] 
111 2977 Italy/2001 blaOXA-58 imipenem-R 82
P (28-3-2-1-4-4-4) [82] 
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Table S2. Geographically and genotypically divergent 129 isolates selected for analyzing the global 
epidemiology of A. baumannii (cont.) 
No. Isolate Country and year of 
isolationa 
Commentb Sequence typec Referenced 
112 3866 Turkey/2003 blaOXA-58 imipenem-R, outbreak-
related 
83P (26-4-2-2-9-1-4) Pasteur MLST, [82] 
113 3871 Turkey/2003 blaOXA-58 imipenem-R 84
P (6-6-8-2-3-5-30) Pasteur MLST, [82] 
114 4389 Greece/2003 - 85P (5-2-4-1-3-3-4) Pasteur MLST 
115 4381 Greece/2003 - 86P (6-30-2-19-31-20-31) Pasteur MLST 
116 ANK29 Turkey/2009 - 95P (1-3-2-2-4-24-2) Pasteur MLST 
117 ANK33 Turkey/2009 - 96P (1-2-36-2-2-2-2) Pasteur MLST 
118 IZM35 Turkey/2009 - 97P (2-2-36-2-2-2-2) Pasteur MLST 
119 ANK17 Turkey/2009 - 98P (1-2-2-2-2-2-2) Pasteur MLST 
120 ANT750 Turkey/2009 - 99P (12-3-18-2-4-4-5) Pasteur MLST 
121 D1 Turkey/2009 - 100P (1-1-1-2-1-1-2) Pasteur MLST 
122 D10 Turkey/2009 - 101P (1-1-1-2-1-1-1) Pasteur MLST 
123 D14 Turkey/2009 - 102P (1-1-1-2-1-5-2) Pasteur MLST 
124 ML Egypt/2010 MDR, blaNDM-2 carbapenem-R 103
P (7-3-2-1-7-1-4) Pasteur MLST, [89] 
125 pla30155 China/2010 MDR 104P (2-2-2-2-2-2-14) Pasteur MLST 
126 pla30104 China/2008 Antibiotic-S 105P (1-2-2-2-5-1-2) Pasteur MLST 





MDR, blaOXA-23-like carbapenem-R, 
SG13 
109P (26-4-2-2-9-1-5) Pasteur MLST, paper 
III 
129 Acb16 Romania/2010 blaOXA-58-like 110
P (3-2-2-4-7-2-2) Pasteur MLST 
aUK, the United Kingdom; USA, the United States of America. 
bRef., reference; Int., international; S, susceptible; R, resistant; MDR, multidrug resistant; SG, sequence group. 
cSTP, sequence type according to Pasteur Institute’s scheme.  
dPasteur MLST, http://www.pasteur.fr/recherche/genopole/PF8/mlst/. 




Table S3. Geographically and genotypically divergent 35 isolates selected for analyzing the global 
epidemiology of A. baumannii 
No. Isolate Country and year of 
isolationa 
Commentb Sequence typec Referenced 
1 RUH 2207 Sweden/1980 Antibiotic-S, sporadic 11B (4-11-6-1-7-8-6)            
53P (1-1-2-2-3-4-2) 
Pubmlst, Pasteur 
MLST, [39, 133] 
2 RUH 875 The Netherlands/1984 
Ref. strain, outbreak-related, int. 
clone I, blaOXA-69 
12B (8-4-4-4-4-5-5)             
109B (10-12-4-11-4-9-5)      
1P (1-1-1-1-5-1-1) 
Pubmlst, Pasteur 
MLST, [39, 131-133] 
3 LUH 5875 The Netherlands/1997 
Ref. strain, MDR, outbreak-
related, carbapenem-S, int. clone 
III, blaOXA-71 
187B (1-1-1-1-1-9-6)               
3P (3-3-2-2-3-1-3) 





The Netherlands/1911 Ref. strain, Antibiotic-S, sporadic 
14B (1-10-10-6-1-4-14)         
26B (1-10-36-22-20-4-24)    
52P (3-2-2-7-9-1-5) 
Pubmlst, Pasteur 
MLST, [39, 133, 143]  
5 ATCC 17978 1951 Ref. strain, Antibiotic-S 112
B (1-12-56-36-1-61-26)  
77P (3-2-2-2-3-4-28) 
Pubmlst, Pasteur 
MLST,  [39] 
6 240 France/2003 blaOXA-23 (Tn2006) carbapenem-
R, int. clone II 
92B (1-3-3-2-2-7-3)                
2P (2-2-2-2-2-2-2) 
[135] 
7 512 Tahiti/2004 blaOXA-23 (Tn2006) carbapenem-
R, int. clone II 
92B (1-3-3-2-2-7-3)                
2P (2-2-2-2-2-2-2) 
[135] 
8 761 Vietnam/2005 blaOXA-23 (Tn2006) carbapenem-
R, int. clone II 
92B (1-3-3-2-2-7-3)                
2P (2-2-2-2-2-2-2) 
[135] 
9 810 New Caledonia/2004 blaOXA-23 (Tn2006) carbapenem-
R, int. clone II 
92B (1-3-3-2-2-7-3)                
2P (2-2-2-2-2-2-2) 
[135] 
10 863 Thailand/2006 blaOXA-23 (Tn2006) carbapenem-
R, int. clone II 
92B (1-3-3-2-2-7-3)                
2P (2-2-2-2-2-2-2) 
[135] 
11 883 Reunion/2006 blaOXA-23 (Tn2006) carbapenem-
R, int. clone II 
92B (1-3-3-2-2-7-3)                
2P (2-2-2-2-2-2-2) 
[135] 
12 859 South Africa/2006 blaOXA-23 (Tn2006) carbapenem-
R, int. clone II 
92B (1-3-3-2-2-7-3)                
2P (2-2-2-2-2-2-2) 
[135] 
13 AS1 UAE/2006 blaOXA-23 (Tn2006) carbapenem-
R, int. clone I 
109B (10-12-4-11-4-9-5)         
1P (1-1-1-1-5-1-1) 
[135] 
14 Ab14 Algeria/2004 blaOXA-23 (Tn2007) carbapenem-
R, int. clone I 
109B (10-12-4-11-4-9-5)        
1P (1-1-1-1-5-1-1) 
[135] 
15 585 France/2004 blaOXA-23 (Tn2006) carbapenem-
R, int. clone II 
118B (1-3-3-2-2-3-3)              
2P (2-2-2-2-2-2-2) 
[135] 
16 BEL Belgium/2007 blaOXA-23 (Tn2007) carbapenem-
R, int. clone I 
245B (10-12-4-11-4-4-5)        
1P (1-1-1-1-5-1-1) 
[135] 
17 614 Libya/2004 blaOXA-23 (Tn2008) carbapenem-
R, int. clone I 
95B (10-12-4-11-1-9-5)        
20P (3-1-1-1-5-1-1) 
[135] 
18 AS3 UAE/2006 blaOXA-23 (ISAba1) carbapenem-
R, int. clone I 
95B (10-12-4-11-1-9-5)        
20P (3-1-1-1-5-1-1) 
[135] 
19 1190 Bahrain/2008 blaOXA-23 (ISAba1) carbapenem-
R, int. clone I 
95B (10-12-4-11-1-9-5)         
20P (3-1-1-1-5-1-1) 
[135] 
20 142HUC Portugal/1999 blaOXA-40 carbapenem-R 98





Portugal/1998 blaIMP-5 carbapenem-R, amikacin-
S, ciprofloxacin-S 
120B (1-3-6-1-4-3-6)             
32P (1-1-2-2-3-4-4) 
Pubmlst, [136] 
22 K71-71 Norway (exported 
from Pakistan)/2009 
MDR, blaOXA-23-like carbapenem-
R, armA, SG4, blaOXA-51 
103B (12-17-12-1-29-3-39)  
15P (6-6-8-2-3-5-4) 
Pubmlst, Pasteur 
MLST, paper II 
23 K58-19 Norway (exported 
from Italy)/2009 
MDR; blaOXA-23-like carbapenem-
R, armA, int. clone II; blaOXA-66 
118B (1-3-3-2-2-3-3)              
2P (2-2-2-2-2-2-2) 
Pubmlst, Pasteur 
MLST, paper II 
24 K61-46 Norway (exported 
from Pakistan)/2009 
MDR, blaOXA-23-like carbapenem-
R, int. clone II, blaOXA-66 
137B (1-3-3-2-2-12-3)             
2P (2-2-2-2-2-2-2) 
Pubmlst, Pasteur 
MLST, paper II 
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Table S3. Geographically and genotypically divergent 35 isolates selected for analyzing the global 
epidemiology of A. baumannii (cont.) 
No. Isolate Country and year of 
isolationa 
Commentb Sequence typec Referenced 
25 K12-21 Norway (exported 
from Greece)/2004 
MDR, blaOXA-58-like carbapenem-
R, int. clone II, blaOXA-66 
189B (1-12-3-2-2-4-3)          
45P (2-6-2-2-2-2-2) 
Pubmlst, Pasteur 
MLST, paper II 
26 K44-35 Norway (exported 
from Thailand)/2007 
MDR, blaOXA-23-like carbapenem-
R, int. clone II, blaOXA-66 
190B (1-3-3-2-2-52-3)            
2P (2-2-2-2-2-2-2) 
Pubmlst, Pasteur 
MLST, paper II 
27 K47-42 Norway (exported 
from China)/2007 
MDR, blaOXA-23-like carbapenem-
R, armA, int. clone II; blaOXA-66 
191B (1-3-3-2-2-94-3)            
2P (2-2-2-2-2-2-2) 
Pubmlst, Pasteur 
MLST, paper II 
28 K48-42 Norway (exported 
from India)/2008 
MDR, blaOXA-23-like carbapenem-
R, int. clone I, blaOXA-69 
192B (10-53-4-11-4-95-5)      
1P (1-1-1-1-5-1-1) 
Pubmlst, Pasteur 
MLST, paper II 
29 K55-13 Norway (exported 
from Cyprus)/2009 
MDR, blaOXA-24-like carbapenem-
R, int. clone II, blaOXA-66 
193B (1-35-3-2-2-3-3)            
2P (2-2-2-2-2-2-2) 
Pubmlst, Pasteur 
MLST, paper II 
30 K55-61 Norway (exported 
from India)/2009 
MDR, blaOXA-23-like carbapenem-
R, SG9, blaOXA-69 
194B (1-15-4-11-4-58-4)      
94P (1-2-2-1-5-1-1) 
Pubmlst, Pasteur 
MLST, paper II 
31 K58-15 Norway (exported 
from Thailand)/2009 
MDR, blaOXA-23-like carbapenem-
R, armA, int. clone II, blaOXA-66 
195B (1-3-3-2-2-96-3)            
2P (2-2-2-2-2-2-2) 
Pubmlst, Pasteur 
MLST, paper II 
32 Ab2941 Brazil/2007 blaOXA-23-like carbapenem-R, int. 









34 HGSA56 Portugal/2007-08 blaOXA-23-like carbapenem-R, int. 
clone II, blaOXA-66 
92B (1-3-3-2-2-7-3)                
2P (2-2-2-2-2-2-2) 
[134] 
35 HGSAI40 Portugal/2008 blaOXA-58-like carbapenem-R, SG4, 
blaOXA-132 
103B (12-17-12-1-29-3-39)  
15P (6-6-8-2-3-5-4) 
[134] 
aUAE, the United Arab Emirates.  
bRef., reference; Int., international; S, susceptible; R, resistant; MDR, multidrug resistant; SG, sequence group. 
cSTB, sequence type according to Bartual’s scheme; STP, sequence type according to Pasteur Institute’s scheme.  
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